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With the advent of whole-genome DNA sequencing technologies, tailoring of
medical treatment to individual patients based on their genetic makeup has become
the vanguard of modern medicine. One such area that can benefit from individu-
alized medicine is that of brain and other Central Nervous System (CNS) cancers.
The prognosis of malignant brain cancers is among the worst due to the hetero-
geneity and complexity of these tumors and their micro-environment. We present
a framework that combines data mining and machine learning techniques with se-
mantic approaches for building a clinically-relevant knowledge base of brain cancer
profiles. We construct clusters of patients based on the similarity of their profiles
using the k-means clustering algorithm and extract relevant molecular attributes
of these clusters to classify instances of the clusters. We create a semantic model
with ontologies, rule checking and reasoning, to enable rational therapeutic regimen
selection. Finally, we lay the foundation to incorporate this framework into a digital
twin architecture of a patient.
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Glossary of Terms
This glossary provides definitions of key terms employed in this work:
DataType Property: DataType Property defines the relation between instances
of classes and literal values, i.e., String using the Protg tool.
Description logic: (DL) is a family of logic-based knowledge representation lan-
guages that can be used to represent the terminological knowledge of an ap-
plication domain in a structured way.
DNA: Deoxyribonucleic acid. A double helix of genetic information vital to the
development, growth and function of living organisms.
Extended Markup Language (XML): The extensible Markup Language pro-
vides the fundamental layer for representation and management of data on the
Web.
Individual: Is a semantic web terminology that represents an instance of a class
in the ontology.
Jena: Jena is an open source Java framework for building Semantic Web and
linked data applications.
Jena Rules: Jena Rules is an inference (reasoning) engine that plugs into Jena.
Model-Based Systems Engineering: Model-based systems engineering (MBSE)
is the formalized application of modeling to support system requirements, de-
ix
sign, analysis, verification and validation activities beginning in the concep-
tual design phase and continuing throughout development and later life cycle
phases (INCOSE-TP-2004-004-02, Version 2.03, September 2007).
mRNA: Messenger RNA. A subset of the family of RNA molecules which carries
genetic information from DNA to the ribosome for protein production.
NCI: National Cancer Institute. The US government’s principal agency for cancer
research.
Neo4J: Graph Database management system developed by Neo4j, Inc.
No-SQL: Not Only SQL databases. A new paradigm of database management
deviating from relational databases. Ideal for large distributed data.
Ontology: A model that describes what entities exist in a design domain, and
how such entities are related.
Ontology Class: A placeholder for an entity in the system design. An ontology
class may have some dataType or objectType properties.
Ontology Instance: An ontology instance is a specific realization of any ontology
class object. An object may be varied in a number of ways. Each realized
variation of that object is an instance. The creation of a realized instance is
called instantiation.
ObjectType Property: ObjectType Property defines the relation between in-
stances (individuals) of two classes in semantic web terminology.
x
Ontology Web Language: The Web Ontology Language (OWL) is a knowledge
representation languages for defining ontologies.
Reasoner (Rule Engine): A semantic reasoner, reasoning engine, rules engine,
or simply a reasoner, is a piece of software able to infer logical consequences
from a set of asserted facts or axioms.
Reasoning: To infer new statements based on set of asserted facts in the ontology.
Resource Description Framework (RDF): a model for encoding semantic re-
lationships between items of data so that these relationships can be interpreted
computationally.
Rule Checking: A mechanism that ensures existing data in the ontology is con-
sistent with rules defined over the ontology. A rule engine performs this task.
Semantic Web: Refers to W3Cs vision of the Web of linked data.
SQL: Structured Query Language. Standard language used to communicate with
relational databases.
SysML: The Systems Modeling Language (SysML) is a graphical modeling lan-
guage used to define models of systems structure and system behavior.
TCGA: The Cancer Genome Atlas. A database of cancer genomics data.
Weka: Waikato Environment for Knowledge Analysis. An open-source suite
of data mining and machine learning tools developed by the University of
Waikato.
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Chapter 1: Complexities of Cancer
1.1 Problem Statement
1.1.1 Cancer: Aberrant Genes
Cancer is a class of diseases characterized by uncontrollable division of abnor-
mal cells. Cancers can develop in nearly all organs and tissues in the body and
can proliferate rapidly forming metastases in secondary sites in the body. Cancer is
the second leading cause of death behind only heart disease; in 2018, an estimated
1, 735, 350 new cases of cancer were diagnosed in the United States [36]. With ad-
vances in medicine, cancer death rates have slowly decreased at an average rate of
1.6% per year over the past fifteen years [36], however much work remains in tackling
the complexities of cancer.
Cancer is characterized as a genetic disease: it is caused by (inborn or acquired)
changes to genes that control the way cells in our bodies grow and divide. Genes are
the basic unit of heredity and contain information necessary for making proteins –
the building blocks and work force of the cells in the body. Genes are parts of long
molecules called Deoxyribonucleic Acid (DNA) which are composed of nucleotides
and are packaged into structures called chromatin and chromosomes. The process
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of reading genes to form proteins involves several steps and is illustrated in Figure
1.1: DNA undergoes transcription to messenger Riboncleic Acid (mRNA), which is
then translated to amino acid chains which fold to make a multiplicity of complex
three-dimensional proteins. Proteins are involved in most cellular functions in the
body ranging from cell signaling to combating viruses and bacteria.
Figure 1.1: Schematic of DNA to protein transformation in cells.
Alterations or mutations in DNA can a↵ect the structure, function and amount
of proteins in cells, which in turn can lead to transformation of normal cells to
cancerous ones. Normal cells are programmed to develop, divide, and die at tissue-
specific intervals. Cancer cells on the other hand develop the ability to resist cell-
death signals, or proliferate at faster rates than normal cells of their tissue of origin.
While the body has several mechanisms for guarding against such growths, if a
su cient number of such cells escape these guards the result leads to formation of
cancerous growths and metastases, as shown in in Figure 1.2.
Not all genetic alternations are detrimental: in fact, genetic variation is what
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Figure 1.2: Di↵erentiation and metastasis of cancer cells.
enables evolution of species and makes us individuals. Two main classes of ge-
netic alterations can lead to cancerous growths: changes that a↵ect so-called tumor-
suppressor genes which produce proteins that guard against abnormal growth, and
changes that create so-called oncogenes which lead to creation of proteins with ab-
normal structure that may, for example, lead to abnormal turning-on of the signal
for the cells to grow and divide. Once aberrant cells develop, they may accumulate
more genetic changes which further lead to faster growth and aggressive behavior.
Each person’s cancer is also unique in its set of genetic aberrations; even within
the same tumor, there can be signficant di↵erences in the genetic alterations between
the cells [11]. With over 20, 000 protein-coding genes within the human genome, and
various levels of regulation of the process of replication, transcription, and transla-
tion, grappling with and understanding the complexity and heterogeneity of cancers
is a monumental task for today’s researchers. Next-generation sequencing technolo-
gies are however making it possible to extract information on genetic aberrations at
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the single nucleotide level and heralding the age of tackling the problem of cancer
at the individual level where each patient’s genome is sequenced and analyzed. This
new era of biotechnology and big data provides opportunities to tailor treatment to
the individual and not just the disease.
1.1.2 Heterogeneity and Complexity of Brain Tumors
Cancer can be classified into di↵erent types based on their location in the
body and their genetic makeup. This thesis will focus primarily on Gliomas which
are the largest subset of brain and Central Nervous System (CNS) cancers and
originate in the glial, neuron-supporting cells in the brain. Primary brain tumors
or neoplasms originate in the brain (as opposed to spreading from other parts of
the body). According to the World Health Organization, there are over 130 types
of primary brain neoplasms [39]. Of these, nearly 32% are malignant, meaning they
divide uncontrollably and 68% are non-malignant. Although not as common as
breast and lung cancers, incidences of malignant brain and CNS tumors range from
5.71 to 10.25 per 100, 000 population in the United States. Brain cancers are also
the most common cancers diagnosed among children aged 0  14 years [39].
The heterogeneity and location present a significant barrier to diagnosis and
treatment of brain and CNS tumors. For example, a study of 1, 122 patient samples
of adult di↵use glioma produced seven di↵erent subtypes based on distinct genetic
signatures [11]. Not only do these tumors di↵er between patients, but also tumors
within individual patients display characteristics from multiple sub-types. As illus-
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Figure 1.3: Profiling of primary Glioblastoma shows cells with di↵erent sub-type
characteristics. Each dot represents a cell. Mes, Neu and Pro represent di↵erent
Glioma subtypes. The location of the cells are based on a classifier score based on
all cells in the tumor [41].
trated in Figure 1.3, profiling of primary Glioblastomas (Grade 4 Gliomas) showed
that within a single tumor itself, cells can have characteristics of di↵erent subtypes
of Glioma [41].
Treatment of brain tumors typically may include surgery, radiation therapy
and/or chemotherapy. Many patients undergo surgery to remove the tumor, which in
most benign cases, is enough to mitigate patient symptoms. Aggressive, malignant
tumors such as Glioblastomas, have a high rate of recurrence, which necessitates
aggressive treatment that includes radiation therapy or chemotherapy. Radiation
therapy is the targeted treatment of cancerous cells using high energy beams such as
X-ray or protons. Chemotherapy, on the other hand, administers drugs that work
to destroy or damage cancerous cells. These drugs most often target DNA and RNA
sequences which halt or slow down cell division. However, many chemotherapy drugs
cannot di↵erentiate between healthy and cancerous cells; this leads to severe side
e↵ects for the patients such as nausea, fatigue, neurological impairment. Advances
in treatment primarily focus on finding gene and protein targets within tumor cells
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that would enable focusing the e↵ect of treatment on cancer cells. More recent
approaches include attempts to recruit the patient’s immune system in the fight
against cancer cells.
1.1.3 Gliomas
The scope of this thesis covers a subset of CNS tumors called Gliomas. Gliomas
originate in glial cells of the brain or the spine. Glial cells support and provide
protection to neurons. Nearly 80% of all malignant brain tumors and 30% of all
brain tumors are diagnosed as some form of Glioma [22].
Types of Glioma. There are four primary types of Gliomas [24]:
Ependymomas Tumors that arise from a tissue called ependyma.
Astrocytoma Tumors originating in a particular glial cell called astrocytes. Astro-
cytoma can be organized into two classes: 1. Narrow Infiltration which are
mostly noninvasive tumors 2. Di↵use Intfiltration which are high grade tumors
with poor prognosis.
Oligodendrogliomas Tumors that originate from oligodendrocytes.
Brain Stem Glioma Tumors that originate in the brain stem.
Gliomas are categorized into grades for diagnosis according to the WHO Clas-
sification of Tumors of the Central Nervous System. The grades are determined by
pathological and molecular evaluation of the biopsy of the tumor. Gliomas can be
characterized as either Low-grade or High-grade:
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Low-Grade Gliomas (WHO Grade 2) Well defined and di↵erentiated tumors that
are more often benign with better prognosis for the patient. The median sur-
vival rate of patients diagnosed is approximate 5.6 to 11.6 years [38]. However,
they can progress into high-grade Gliomas.
High-Grade Gliomas (WHO Grade 3-4) Ill defined and undi↵erentiated malignant
tumors that have a worse prognosis. The median survival rate is approximately
3 years. Glioblastoma multiforme is the most malignant of the high grade
tumors with a median survival rate of around 8.8 months [38].
The exact causes for the formation of gliomas are still unknown but, as with
most other cancers, Gliomas form due to genetic abnormalities that a patient de-
velops or is predisposed to. Access to recent molecular characterization studies of
Glioma diagnosed patients have shown that certain molecular characteristics define
cohorts within the disease with varying prognosis, that is, likely course of disease [11].
In particular, mutations in the Isocitrate Dehydrogenase I and II gene (IDH1/2) de-
fine a subset of Glioma, which along with a specific hypermethylation phenotype
shows favorable prognostic outcomes. On the other hand, patients with una↵ected,
or “wild type” IDH1/2 have poor prognosis. As depicted in Figure 1.4, the study
of 1,112 Lower Grade Glioma and Glioblastoma patients can be clustered based
on di↵erent molecular characterizations. These clusters are shown to have varying
survival rates, age of diagnosis, grade and histology. It is evident that a molecular
characterization e↵ort to understand and define such clusters can aid a physician in
determining the likely prognosis. In this thesis, we use a similar approach to clus-
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ter patients based on molecular data and derive functional attributes that enable
creation of tumor models to select patients and preclinical models.
1.2 Formalizing Brain Tumor Profiles
1.2.1 Precision Medicine: Whole Genome Sequencing
Diagnosis of common illnesses today is based on symptoms of the patient
and other non-molecular clinical factors. With illnesses such as the common cold,
this is adequate, however, when dealing with complex diseases such as neurological
ailments, there are more nuances that a clinician will have to account for. With the
advent of new medical technologies, medicine is shifting from treating the disease to
treating the individual. The realization that each of us are biologically unique has
led to “omic” assessments that integrate an individual’s DNA, RNA and protein data
to aid in the diagnosis of the disease [54]. This section provides a brief introduction
to the sate of current medical technologies and methods that can be leveraged for
precision medicine.
The sequencing of the human genome and the rapid advancement in the speed
and reduction of costs in using such technology has been one of the most important
achievements of the past two decades. DNA sequencing works by first segmenting
the DNA into smaller pieces and copying the DNA multiple times over using bac-
terial cells. The DNA then undergoes a cycle of copying where a nucleotide base
attached with a fluorescent tag is added to the final base of the DNA fragment. At
the end of this process, a machine is able to read the bases based on the wavelength of
8
(legend on next page)
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Figure 1.4: Molecular characterization of Adult Di↵use Glioma produces seve dif-
ferent cohorts with varying survival rates, age of diagnosis, grade and histological
characteristics.(Source: Caccarelli, et al. [11])
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the fluorescent tag. High-throughput sequencing of the genome can be done within
3 to 4 days [54], allowing access to the genetic information of the patient. With this
sequencing, the molecular basis of rare or low-frequency variants of diseases have
been uncovered [54]. Single-Cell sequencing, the sequencing of the genomic material
of individual cells, has also been a major factor in providing insights into disease.
DNA sequences obtained from multiple cells within a tumor have shown that there
is even heterogeneity amongst the cells of the same tissue [11]. DNA sequences allow
physicians to ascertain if there are any mutations or other structural changes (for
example, additional copies, deleted copies, fused genes, or insertions of viral DNA)
in a person’s DNA. As the technology improves and the costs fall, more people will
have access to these diagnostic tools, creating vast data sets that can be assessed in
detail to be used functionally.
DNA provides a rather static view of the cell; RNA, on the other hand pro-
vides a dynamic view of the state of the cell. RNA is the precursor to protein in
the cell; a RNA based assay shows what is being produced in the cell at the time
of the assay. Although not as streamlined as genome sequencing, RNA sequenc-
ing technologies are a relatively new set of tools that provide a dynamic view of
the patient. These tools capture data on gene fusions, spliced transcripts and the
whole gamut of RNAs including microRNA, and ribosomalRNA [54]. With RNA
sequencing, physicians are able to quantify cellular changes between a healthy and a
diagnosed patient. Theses changes, usually measured as mRNA expression, enable
physicians to understand which genes are active and inactive for a certain disease
and enable targeting of pathways associated with the translation of such genes.
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Epigenetics is the study of the modification in gene expression through regu-
latory molecules that a↵ect the genetic code. The epigenome consists of chemical
compounds that instruct the genome what to do without altering the code itself.
These compounds usually attach themselves to DNA and can turn on or o↵ DNA
to direct protein expression. Of the myriad of compounds, methyl groups – three
hydrogen molecules attached to a carbon molecule – have been mapped extensively
within 200 di↵erent cell types of the body [54]. Unusual epigenetic markers often
indicate altered states within cells and this can be leveraged to di↵erentiate diseases
and find potential pathways for drug-targeting.
Figure 1.5: The integration of patient data from the genome to the patient’s en-
vironment is paving the way for new treatment and diagnostic paradigms (Source:
Topol [54])
It is evident from Figure 1.5 that the paradigm of treating the disease is
shifting to that of treating the patient. With the availability of data from di↵erent
domains, it is now possible to digitize the patient. The key going forward will be
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the development of new frameworks and algorithms used in conjunction with the
integrated data set. In this thesis, we integrate data from the genome in the form of
mutations and copy number changes, from the epigenome in the form of methylation
sites and from the transcriptome in the form of mRNA expression. We provide a
framework that integrates information from these dimensions of the patient genome
and utilize the multi-dimensional data to generate models and rules that can guide
clinical decisions for patients diagnosed with Gliomas.
1.2.2 Preclinical Models
Before a new cancer drug can undergo clinical trials, which test the therapy
on human patients, they must undergo extensive preclinical studies. Preclinical
studies are performed on (experimental) model systems. The two main categories
of experimental models are: In Vitro-cell cultures, where cancer cells (originating
from humans or animals) are grown in Petri dishes under controlled conditions and
subjected to experimental treatments; and In Vivo-animal models, where cancer
cells are implanted in a live animal, or cancer is induced to form in the animal
and the treatment is administered to the animal. These cell and animal models are
an integral part of the extensive preclinical studies performed to understand the
e cacy and potential toxicity of new cancer drugs. The drug development life cycle
depicted in Figure 1.6, is composed of drug discovery, preclinical trials, clinical trials
and FDA reviews and approvals. The development of a drug is often a decade long
process with the majority of the time spent in development and preclinical testing.
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Figure 1.6: Timeline for drug discovery and development.
Animal and cell models have been a mainstay of preclinical testing. However,
the complexity of aggressive cancers, and their interplay with other systems of the
organism (immune, organ, cellular) make it impossible for the cell line and animal
models to faithfully represent the human disease [29]; therefore, even therapies that
are proved successful in preclinical studies often fail to show e cacy in clinical trials.
In fact, only about a third of highly cited preclinical trials enter clinical trials, and
out of those only about 8% of these drugs pass phase 1 of clinical trials [29].
Recent e↵orts such as the Cancer Cell Line Encyclopedia [7], have profiled
and compiled genetic characteristics of cancer cell lines and their response to a
collection of drugs, in search of genetic predictors of drug sensitivity [7]. In this
thesis we develop a framework that will enable characterization of patient cancer
profiles alongside cell line profiles, and reasoning about their similarity. We will
identify genetic markers that characterize molecular subtypes within Gliomas and
use these markers to identify preclinical models that share similar genetic charac-
teristics. With a data driven semantic model, we hope to bridge the translational
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barrier between preclinical and clinical trials.
1.3 Project Vision: Systems Support for Personalized Medicine
The long-term objectives of this work are to develop and validate methodolo-
gies and tools for the personalized treatment of brain cancer patients. The proposed
approach employs ideas in systems development with design platforms and digital
twins, and is supported by semantic modeling/machine learning techniques for rea-
soning with medical domain knowledge and various forms of patient-specific data.
1.3.1 Design Platforms
Design is a transformational process that takes a specification and turns it
into a product. The way in which this process is organized is called a methodology.
As systems become progressively more complex, and time-to-market constraints
progressively more stringent, the relative cost of systematically exploring design
spaces to find good designs, and then verifying and testing behavior will steadily
increase unless new approaches are developed.
We define platform-based design [48] as the creation of a stable architecture
that can be rapidly extended, customized for a range of applications (instead of a
single product), and delivered to customers for quick deployment. Platform-based
design methodologies improve the e ciency, correctness and economics of design by:
(1) restricting the space of design options to pre-defined components, connectors,
and rules for assembly (all contained in a library), and (2) providing designers with
14
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Figure 1.7: Platform-based design for diagnosis and treatment of cancer patients.
the ability to look ahead and reason with libraries of available options. Design is
more e cient because an engineer working on abstraction level n can improve the
quality of decision making by looking ahead to information at lower-level abstraction
levels (n+1, n+2, ...). The latter reduces both the number of required iterations
of development and large loop corrections. Design is more correct because systems
can only be assembled from components and connectors that have already been
developed and are known to work.
While these techniques were initially developed in the late 1980s and 90s for
the design of electronic, automotive and aircraft systems [26,47,50], it is now evident
that the same approaches add value to the design of experiments needed for accurate
development of biomedical devices [34]. A second emerging opportunity is synthesis
of patient treatment plans in the medical domain. As a case in point, Figure 1.7
shows how the design of patient treatment plans can be viewed as a meet-me-in-
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the-middle process where a top-down refinement of patient’s medical condition and
constraints on medical treatment (i.e., patient/medical application space), meets
with an architecture (glioma models and treatment options) space of potentially
good implementations for treatment of patients, plus constraints and measures of
e↵ectiveness for evaluating success.In order to capitalize upon the added capabilities
of such a technique, two key tenets of this work are that: (1) methods to succinctly
model a breadth of biological systems must be developed, and (2) these models must
be able to integrate with system-level models capable of describing the performance
of the entire doctor-patient-healthcare system. Current methods and techniques for
cancer patient treatment are simply are not capable of such full-system modeling.
1.3.2 Digital Twin Architectures
While platform approaches to design focus on e ciencies at the the front-
end of system development, digital twins are expected to provide decision making
support throughout the system life cycle. For the application domain at hand, this
corresponds to the complete period in which a cancer patient is provided medical
treatment.
A digital twin is a cyber representation of a system that mirrors its implemen-
tation in the physical world; this is achieved through modeling of system structure
and behavior plus real-time monitoring and synchronization of data associated with
events. The latter are made possible by remarkable advances in sensing, communi-
cation, and AI technologies that have occured over the past few decades. From a
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Figure 1.8: Digital twin architecture for personalized medicine.
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Figure 1.9: Semantic modeling integrating multiple domains using rules and infer-
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Figure 1.10: Abbreviated digital twin architecture for a combined semantic and
machine learning approach to real-time monitoring and treatment of cancer patients.
Focus areas for this thesis are highlighted in blue.
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temporal standpoint, the associated software and algorithms work to provide sim-
ulation and optimization support for forecasting of near-term system performance
and long-term planning. The digital twin concept [21] was initially proposed in
the 2000-2010 era as a way to support the design and operation of air vehicles
for NASA. Since then the range of potential applications has expanded to include
automotive components, manufacturing processes, power plants, and smart cities,
among others [21,27,33]. Within the systems engineering community, Siemens now
sees digital twins being the successor to procedures for model-based systems engi-
neering [10]. The associated view within the healthcare community is that digital
twin technologies that embrace open ecosystems and services can open the door to
improved clinical services and improved economics [18].
Figure 1.8 is a high-level schematic for digital twin architecture for personalized
medicine. In this setup, streams of patient data will be collected by wearable devices,
integrated with a patient’s clinical data and transmitted to a “patient” digital twin
that works as an operating system to identify medical events and then match details
of the biological-patient terrain to feasible plans for health treatment.
1.3.3 Combined Semantic and Machine Learning Approach
This work explores a combined approach to formalizing brain cancer profiles,
where semantic models and machine learning techniques work collaboratively as a
team to represent and reason with various types of patient data and medical domain
knowledge to determine recommendations for doctor action and patient treatment.
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The interaction of semantic modeling and machine learning techniques can be
succinctly represented by the architectural template shown in Figure 1.9. Semantic
models are ideal for the development of ontologies and inference rules of the Glioma
domain. In contrast, basic machine model are ideal for the identification of classifi-
cation, clustering and association relationship in data, and for the identification of
anomalies in streams of patient data. The architectural template employs feature
engineering [57] that allows to find or define features that enable ML algorithms
to work. Feature engineering begins with raw data from which relevant or use-
ful features are extracted and formatted as inputs of the ML algorithm. Clustering
identifies groups of objects in the domain that are related and decision tree classifiers
identify rules that maximize the likelihood of prediction for a target. Association
algorithms look for rules that strongly correlate di↵erent features of data that enable
the creation of rules that can span multiple domains. Finally, this template allows
dynamic changes to the knowledge base where new data can be easily ingested and
rules likewise updated.
Figure 1.10 takes the architectural template and customizes it to cover the
range of concerns one might see in a full implementation of the project vision. The
individual rows – data, ontologies and rules – represent the various domains of
interest, including those already introduced in Figures 1.5, 1.7 and 1.8. The lower
portion of Figure 1.10 depicts how ontologies are imported into a semantic graph,
rules are executed via a reasoner, and how the semantic graphs responds to any
incoming data or events triggering a graph transformation.
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1.4 Thesis Contributions and Organization
Figure 1.11 is a flowchart of the research activities covered by this thesis. On
the semantic side of the problem, the scope of investigation covers development of
ontologies and rules for domains highlighted in blue in Figure 1.10. These activities
are supported on the machine learning side with procedures for clustering and clas-
sification of patient data. The clustering and classification analyses are handled by
MATLAB and Neo4J, and Weka, respectively.
Sources of Data. Lower Grade Glioma and Glioblastoma patient data was ob-
tained from The Cancer Genome Atlas (TCGA). TCGA is a program initiated by
the National Cancer Institute to molecularly profile over 20,000 patients samples
covering 33 di↵erent cancer types [53]. A comprehensive overview of the data is
provided in Section 3.1.1.
Contributions. The contributions of this thesis are as follows:
1. We propose that a semantic approach to the CNS cancer domain will lower the
translational barrier of laboratory therapies not e↵ectively working in clinical
trials by:
• Enabling the rational selection of preclinical models.
• Enabling selection of patients for clinical trials based on similarity to such
models.
In order to accomplish this, we provide the initial steps and framework to
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Figure 1.11: Flowchart of research activities covered by this thesis.
create a semantic model that incorporates patient genome data to be used
for model selection. We utilize the Semantic Model and Machine Learning
Architectural template [4,12] to create a semantic model that encompasses the
Glioma domain with rules that allow mapping of patients to relevant preclinical
models.
2. We develop prototype ontologies and rules for:
Glioma Ontology A simplified knowledge graph of terms associated with Glioma,
including sub-types with their hierarchical relationships.
Patient Ontology A knowledge base of terms and data types associated with
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features relevant to a patient.
Cell Line Ontology A simplified knowledge graph of attributes and terms as-
sociated with cancer cell line models.
Mapping Rules Rules derived from ML algorithms that enable mapping of
patients and cell line models to prognostically relevant clusters.
Individuals Instances of patients and cell line models ingested into the ontol-
ogy from di↵erent data sources.
3. We provide a framework for tackling high-dimensional whole genome sequenced
data by employing ML algorithms to cluster data into similar clusters. We
then utilize classifier algorithms to extract features that are relevant to these
clusters to be used in the mapping of the patients to the models.
4. We provide a graph database of the data and the results. We employ the Neo4j
graph database platform to store, query and validate the data. The database
allows for the querying of relevant clinical and molecular attributes of each
cluster and individual patients and allows for visualization of the clusters.
Organization. The thesis is organized as follows: Chapter 2 covers related work in
semantic modeling and semantic web technologies, and basic capabilities of machine
learning. Chapter 3 provides the framework to use unsupervised ML to create
clusters from high-dimensional patient genome data and the creation of a graph
database to query and visualize clusters. We provide an overview of the data used
for analysis and the formal description of the k-means clustering algorithm used to
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cluster the data. Chapter 4 provides a formal description of the classifier algorithm
and its results extracting features from the clusters. Chapter 5 describles the steps
and tools used to create the Glioma specific Semantic Model. We also provide an
application of the semantic model in mapping preclinical models to prognostically
relevant clusters. Finally, Chapter 6 provides the conclusion and future work
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Chapter 2: Related Work
2.1 The Semantic Web
2.1.1 Semantic Web Technologies
The World Wide Web is a network of machines that allow linking of docu-
ments through hyperlinks. It was created with the initial purpose for the sharing
of information among members of the scientific community. Early versions of the
World Wide Web only allowed for the retrieval of documents and interpretation of
these documents by the end-user. The Semantic Web is an extension of the World
Wide Web that aims to imbue semantic data into the network allowing machines to
access, share and automatically discover new knowledge [23,49].
Applications that access data from many sources and from large databases will
benefit from the automatic machine aided assistance in the creation of knowledge.
To this end, the Semantic Web utilizes markup languages to introduce, coordinate
and share semantic data and o↵ers the ability to reason and draw inferences via
ontologies. The Semantic Web provides an ideal framework to create models that
integrate di↵erent domains, react to new data and allow for automatic reasoning;
all of which will be crucial for precision medicine.
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Figure 2.1: The Semantic Web Layer Technologies (Source: Feigenbaum, L. [17]).
Figure 2.1 presents the technical infrastructure supporting the Semantic Web
and the framework to construct and employ a semantic model. Each layer is built
upon the capabilities of the lower layer with the top-most layer providing interfaces
for applications with the intent of knowledge discovery and reasoning. URI and
Unicode allow for identifying resources on the web and linking documents. The
extensible Markup Language (XML) provides the layer for representation and man-
agement of data. XML allows semantic web applications to gather information from
various sources on the web. Resource description framework (RDF) allows repre-
sentation of the data from web sources in a graph model. The graph representation
of data allows for the hierarchical representation and querying of data. Finally,
the web ontology language (OWL) provides semantic meaning to the model and
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the data. These technologies in conjunction provide a framework for reasoning on
multi-domain data, which for precision medicine applications, is a crucial element
for knowledge codification and creation.
2.1.2 Web Ontology Language (OWL)
Description Logic (DL) are a family of formal knowledge representation lan-
guages used in artificial intelligence to represent and reason about concepts of a
domain. DL is used in the biomedical domain to codify and reason over biomed-
ical knowledge. In information science, ontologies capture a domain’s definitions,
properties and/or attributes of data, classes, relations and individuals (or instances).
Ontologies are analogous to a class hierarchy and datatypes found in object-oriented
design (OOP). Unlike OOP, ontologies capture domain structure that assert rela-
tionship of domain entities (e.g.: subClassOf) and enable reasoning over multiple
domains.
The Web Ontology Language (OWL) is a DL-based knowledge representation
language used for the construction of ontologies [1]. OWL is built upon the RDF
concept and adds structure and vocabulary for describing properties and classes.
OWL allows property definitions, class restrictions and hierarchies and provides an
infrastructure to use first order logic to reason and infer new knowledge. Figure 2.2
presents an example of how a domain entity, a car, is captured in OWL.
In Figure 2.2, Company, Factory and Car are classes which have their own defi-
nition and attributes already defined in their respective ontologies. The relationships
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Figure 2.2: An OWL graph of attributes and relationships describing a car.
between di↵erent domain entities (hasManufacturer and hasLocation) are object
properties that specify a relationship between a pair of resources or nodes. Date
and String are connected via datatype property (hasCompletionDate and hasType)
and are akin to datatype in OOP. Figure 2.3 shows how OWL represents these
nodes and relationships formally. OWL is powerful in that it provides a framework



























Figure 2.3: OWL definition of a car.
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2.1.3 Jena and Jena Rules
Apache Jena [2] is an open source Java framework that allows creation of Se-
mantic Web data applications. Jena is primarily used to create and manipulate
RDF (resource description framework) graphs and provides APIs that enable de-
velopers to utilize OWL (web ontology language) and SPARQL (RDF graph query
support) frameworks. Once a semantic model is created, Jena supports the query-
ing, transformation and reasoning of the model. Jena provides standard but limited
querying capabilities which span from listing all the statements in the model to
selecting statements based on attributes and/or subjects. It also provides three
operations; union, intersection and di↵erence to merge and manipulate data from
disparate sources. Finally, Jena provides a reasoning platform to dynamically alter
the semantic model and to infer knowledge.
Jena utilizes a rule-based reasoning approach; the knowledge-based system is
developed by deduction, induction and abduction methods from a starting set of data
and rules. Jena provides inference engines or reasoners to utilize and transform the
semantic model. Reasoners provide means to derive additional RDF statements from
a base RDF graph with ingestion of new data and the axioms and rules associated
with the reasoner. Jena Rules reasoner engine is used as part of this thesis. The
RDF knowledge graph along with the reasoner makes the semantic model a dynamic
and responsive model capable of integrating multi-domain data.
30
2.2 Semantic Modeling: Ontologies and Rules supported by Data
Figure 2.4 presents a framework for the implementation of semantic models
using ontologies, rules, and reasoning mechanisms. From a data science commu-
nity perspective, an ontology is a set of knowledge terms that includes vocabulary,
semantic interconnections, and some simple rules of inference and logic for some
particular topic [23]. To provide a formal conceptualization within a particular
domain, and thereby facilitate communication and reasoning among domains, on-
tologies need to accomplish three things: (1) Provide a semantic representation of
each entity and its relationships to other entities, (2) Provide constraints and rules
that permit reasoning within the ontology, and (3) Describes behavior associated
with stated or inferred facts.
System data models contain the data and relationships among data needed to
build models of system structure and system behavior. For medical domain models,
this information will consist of catalogues of knowledge defining the disease space,
positioned alongside data collected from specific patients. The semantic counterpart
of medical domain models is ontologies (class hierarchies), individuals (graphs), and
rules. Data contained within the medical domain models will be ingested into the
semantic model as data property values. Relationships (including dependencies)
among the various classes will be represented as object properties. For the semantic
modeling of complex multi-domain applications it is common practice to organize
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Figure 2.4: Framework for semantic modeling in medical domain applications.
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illustrate, for example, one such organization for the brain cancer domain. Patient,
symptom, and patient treatment ontologies are directly applicable to our domain
of interest, but also apply to the solution of medical problems outside brain cancer.
They can import and use top-level ontologies representing general concepts such as
time, space, and physical units that apply to and cut across many domains. One
important di↵erence between many engineering systems and the medical domain is
that the latter is concerned with systems that are living. The basic formal ontology
(BF0) [3] is an e↵ort to provide medical practitioners (among others) with sets of
carefully designed ontologies for the description of general concepts. BFO has found
considerable success in the medical and biomedical domains [51].
Rule-based approaches to problem solving provide several advantages: (1) rules
that represent policies are easily communicated and understood, (2) rules retain
a higher level of independence than logic embedded in systems, (3) rules separate
knowledge from its implementation logic, and (4) rules can be changed without
changing source code or underlying model [46]. They are particularly beneficial
when the application logic of a problem domain is dynamic, and where rules are
imposed on the system by external entities. These conditions apply to a wide
range of problems in systems engineering and analysis (e.g., semantic modeling for
cyber-physical systems [14, 15, 42], traceability of requirements to component-level
behaviors [13], component-based modeling, design and trade-o↵ analysis with RDF
graphs [35], validation of connectivity relationships in component-based systems [6]
and behavior modeling of distributed systems [5]).
33
2.3 Machine Learning: Uncovering Patterns in Data
Modern-day machine learning (ML) techniques provide insights - sets of pat-
terns and behavior - to large amounts of data. These techniques and tools are used
ubiquitously in domains ranging from smart cities and buildings [4, 16] to bioinfor-
matics. Raw data, especially in the case of whole genome patient data, is often, to
the beholder, a monolith with no discernable dependencies or patterns that can be
easily modeled from first principles. However, today’s ML and data mining tools
leverage statistical methods to extract functional data from large data sets to be
used for diagnostic and prognostic needs. This section provides a brief overview of
the two primary flavors of ML and their application to this thesis.
ML techniques can be divided into two broad categories, unsupervised and
supervised learning.
1. Unsupervised learning tries to find the underlying structure and pattern to a
set of data where no label or ‘right answer’ is specified. Unsupervised learning
attempts to decipher what features of the data can be used to find partitions
or labels in the data that can be modeled. Common unsupervised algorithms
include k-means clustering and convolutional neural networks. Labeling of
patient data is often at the diagnostic level based on disease histology and
identification of a set of key biomarkers. For prognostic purposes, it is required
to go deeper into the data to find what specific attributes contribute to di↵erent
variations of the same disease. Adult Glioma, for example, can be divided into
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Figure 2.5: The figure on the left illustrates supervised learning where natural group-
ings of data is sought and the figure on the right illustrates unsupervised learning
where these natural grouping are mapped.
distinct subsets that have variable survival rates, patient age and other clinical
attributes based on each patient’s molecular features [11]. These kinds of
problems can be categorized as clustering problems where groups of instances
or examples that belong together are sought. We use the k-means clustering
algorithm to ascertain similar clusters based on each patient’s molecular profile
and identify those clusters which are relevant for prognosis. Once the clusters
are deemed clinically relevant, we are then able to label patients based on
the clustering and run supervised ML algorithms to ascertains features that
distinguish the clusters.
2. Supervised learning di↵ers from unsupervised learning in that it finds patterns
and mappings of a data set based on user-specified or predetermined labeling
of a training data set. Supervised learning is a form of classification learning
where the learning scheme is presented with a set of classified examples or a
training set from which it is expected to learn a way of classifying unclassified
35
data. Supervised ML has two steps: (i) Training (ii) Prediction. The training
step uses probabilistic models to create decision models or functions that best
mirror the mappings specified by the training set. The prediction step uses
the derived model and applies it to the dataset to calculate the e↵ectiveness
of the model.
The k-means algorithm provides labels to each instance of the data based on molec-
ular similarity. This labeled set of data will then become the training set for the
classification investigation. We utilize the J48 data mining algorithm, a Weka based
java implementation of the C4.5 algorithm [43,56], to create decision trees that al-
low classification of patients based on their molecular profile. The decision tree
provides rules that enable us to map data, without any labels, to a prognostically
relevant cluster.
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Chapter 3: Leveraging Patient Similarity for Clustering
3.1 Finding Patient Clusters Based on Profile-Similarity
3.1.1 Patient Data
There has been a concerted e↵ort to profile cancers based on their molecular
makeup. The Cancer Genome Atlas (TCGA) was one of the largest-scale e↵orts
that aimed to generate, analyze, and interpret molecular profiles at the DNA, RNA,
protein, and epigenetic levels [53]. This e↵ort has led to the creation of a data set
that allows for the comparison and contrast of multiple tumor types. The data set
includes molecular and clinical data from more than twelve di↵erent tumor types;
Glioblastoma, first, and later Lower Grade Glioma and Glioblastoma, were also
profiled as part of TCGA.
Previous work using the Cancer Genome Atlas data have incorporated multiple
dimensions of the TCGA omic characterizations [9]. In our approach we work with
four of the seven TCGA omic characterizations in Figure 3.1: Mutations, Copy
Number, DNA methylation and mRNA expression. Clinical data is also added to
the database but not used for clustering analysis. By combining these di↵erent
characterizations or patient views, we hope to get a more comprehensive definition
37
Figure 3.1: The Cancer Genome Atlas Integrated Data set. (Source: Weinstein, et
al. [53])
of patient similarity for clustering analysis.
The sample set derived from TCGA are all patients diagnosed with brain
tumors; specifically Glioblastoma and Lower Grade Glioma. The total sample set
consists of 1,019 patients, each with four di↵erent patient views: Mutation, Copy
number, mRNA expression and DNA methylation. Each patient view consists of
approximately 11,000 genes. So in total, there are approximately 44,000 units of data
for each patient sample. The values for each gene in each patient view are normalized
to 0 (low), 1 (intermediate) or 2 (high) for Copy Number, DNA Methylation and
mRNA Expression and simply 0 (no mutation) or 1 (mutated) for mutations.
Patient Views. The four di↵erent patient views are defined as follows:
Mutations Nucleotide alterations in a gene where a single or multiple nucleotide base
pair(s) are altered due to DNA copying errors. Mutations may cause changes
in protein structure and expression. Values are binary with 0 meaning no
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mutation and 1 meaning mutation.
Copy Number Repetition or deletion of long sequences of nucleotides. These often
arise from incorrect repair of DNA damage and may result in aberrant protein
expression. For each gene, values are normalized across the cohort to 0: low
copy number, 1: intermediate copy number, and 2: high copy number.
DNA Methylation Process by which methyl groups, composed of carbon and hy-
drogen molecules, are added to the DNA molecule. This process a↵ects how
much of the DNA is active without changing the sequence. For each gene,
values are normalized across the cohort to 0: low degree of methylation (also
known as hypomethylation), 1: intermediate degree methylation, and 2: high
degree of methylation (also known as hypermethylation).
mRNA Expression Measurement of how much mRNA is produced from particular
genes. For each gene, values are normalized across the cohort to 0: low level of
expression, 1: intermediate level of expression, and 2: high level of expression.
TCGA clinical data for each of the samples was used to assess prognostic significance
of the identified clusters. Once clustering analysis using the molecular patient views
was conducted, overall survival information was used to calculate Kaplan-Meier
survival. The Kaplan-Meier survival assesses whether the clusters identified using
their molecular characteristics, contained prognostic value.
Patient Clinical Data. The patient clinical attributes are defined as follows:
Sample ID A TCGA ID unique to each sample.
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Sex The sex of the patient.
Race The race of the patient.
age The age of the patient.
AgeQ2 The normalized age of the sample to the whole sample set.
Time The survival time of the patient measured in days.
TimeQ2 The normalized survival time of the patient to the whole sample set.
Status The status of the patient, with 1 being alive at last follow up or study end
and 0 being deceased.
It is to be noted that for methylation and mutation studies, a significant
portion of the GBM patient molecular data is unavailable. This is due to the
fact that the TCGA program spanned over a decade with GBM being one of the
pilot studies. With advances in profiling technologies, studies done after GBM,
such as LGG, were conducted using newer technologies and streamlined methods
leading to better data availability. More sequencing data is available under protected
availability but not used for this thesis.
3.1.2 Calculating Inter-Patient Similarity
With high dimensional patient data that contains thousands, if not, millions
of data points, brute-force statistical and machine learning methods are ine cient
to find patient groups. Hence, the Jaccard index was calculated to discover patient
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groupings based on inter-patient similarity. The Jaccard index measures similarity
between any number of non-empty finite sets and is defined as the intersection over




|A [ B| =
|A ^ B|
|A|+ |B|  |A [ B| (3.1)
MATLAB was used to calculate the Jaccard index between each sample. Each
patient view was downloaded as a matrix from a text file. Data for each patient
view contained integers for genes with available data and the string ‘NA’ for genes
with no data. The following algorithm was used to generate the intersection and
the union for each patient view:
for Number of Patient Samples do
for Number of Genes do
if Both Patients have Integer data then
increment the count of the union of the two patients by one;
end
if Both Patients have identical Integer values then




Result: Two 1019x1019 matrix that contain the Union and the Intersection.
Algorithm 1: Algorithm to calculate the Jaccard Index for each Patient View
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A total of eight 1019x1019 matrices were generated; four for the intersection
and four for the union of each patient view. For each of the patient views, the
respective intersection matrix was divided by the union matrix to calculate the
jaccard index matrix. The jaccard index matrix for each of the four patient views
were then averaged together to create a correlation matrix that contained the jaccard
index of how similar a sample is to another. The final result is a 1019x1019 matrix
which contains the Jaccard index for each patient sample to the rest of the samples.
Each value in the matrix corresponds to the Jaccard index between the patient
represented by the row number and the patient represented by the column number.
3.1.3 k-means Clustering Algorithm
Clustering techniques are applied when there is no class to be predicted but the
instances can be assigned or partitioned into natural groups or clusters. A cluster
is defined as an aggregation of data points or vectors based on similarity. The k-
means algorithm is an unsupervised clustering algorithm that partitions data into
k mutually exclusive clusters. The algorithm iteratively tries to assign each data
vector to a cluster based on the features provided. The goal of the algorithm is to
create the specified k centroids and reduce the sum of squares of all the data points







||xji   cj||2 (3.2)
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where ||xji   cj||2 is the euclidean distance between a data vector x
j
i and a centroid,
cj. k is the number of clusters specified and m is the total number of data points.
Note that xmi can be an n-dimensional vector.
The algorithm iteratively minimizes the sum of squares for each of the clusters.
It begins with assigning k centroids and iteratively moves the centroids until the best
minimization is found. Figure 3.2 is a graphical representation of each iteration of
the algorithm in 2-D space. It is composed of the following steps:
1. Place k random points in the n-dimensional space of all the data points as far
away from other points. These are the initial centroids.
2. Assign each data point to the closest centroid. Closeness is calculated as the
euclidean distance between the data point and the centroid.
3. When all data points have been assigned, take the average of the points in the






cj is the new centroid position, ncj is the number of data points in the cluster
and xj are the data points in the cluster.
4. Repeat steps 2 and 3 iteratively until the centroids do not move.
K-means is easy to implement and is one of the best clustering algorithms
to run on large data sets. Compared to other clusters, the computational cost of
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Figure 3.2: K-means clustering in 2-D space.
k-means is low; with a complexity of O(K*m*n), where k is the number of clusters,
m is the number of data points and n is the dimensions of the vectors. However, k-
means can only be used on numeric data sets and perform better where the clusters
are more spherical. Another caveat of the algorithm is specifying the number of
clusters to partition the data into. It is not always evident what the optimal k
value should be, however methods such as the elbow method and silhouette method
can be utilized to narrow down to a range of k values. The algorithm is a built-in
function in MATLAB, and requires as inputs the data matrix and the number of
clusters k, and outputs the cluster ID of each sample and the centroid locations.
The elbow method was used to determine the minimum k value for the data set.
The method works by running the k-means algorithm from 1 to k times iteratively
on the data set, and measuring the total sum of squares of all the data from each
cluster. The initial few clusters will have a high sum of squares value but, as the
number of clusters increase the total sum of squares will drop precipitously. As the
44
Figure 3.3: The Total sum of squares vs. the number of clusters identify a k value
of 5 as the minimum value when evaluating k values from 1 to 10.
process continues, there will come a point at which adding a new cluster will only
decrease the total sum of squares marginally, at which point, an angle will develop
in the plot of the number of clusters versus the total sum of squares. This point
denotes the minimum k value for the data set.
Previous work using the TCGA data sets selected 7 clusters of Glioblastoma
and Lower Grade Glioma diagnosed patients [11]. For our data set, we explored k
values ranging from 2 to 10 clusters. As depicted in Figure 3.3, the elbow is created
at a k value of 5. The result of the elbow method suggests that for the patient
correlation matrix, a minimum k value of 5 is adequate to decrease the total sum of
squares of the data. Any k value higher than 5 will give us clusters with relatively
low sum of squares, whereas any value lower than 5 will have a high total sum of




Based on the results of the elbow method detailed in section 3.1.3, we ran
the k-means method with k values from 5 to 9. This produced five di↵erent data
sets with the patient samples clustered into 5, 6, 7, 8 and 9 clusters respectively.
For each data set, we performed the Kaplan-Meier overall survival analysis [25] and
the Log Rank test [30] to determine if overall survival of patients from di↵erent
clusters were statistically di↵erent. That is, we wanted to identify if the partitioned
clusters validly captured a cohort of the population with a di↵erent survival rate.
A statistical significance between the clusters would indicate a di↵erence in the
prognosis of the patients in the cluster compared to other patients.
The Kaplan-Meier Test estimates the probability of survival at each point in
time [25]. It is used to compute a population survival function from the survival
time and status (alive or dead) for patients. Survival time is measured as the unit of
time a patient is alive after diagnosis and is updated each time a patient comes in for
a follow-up. Kaplan-Meier also takes into account censored data where the patient
data is missing after a period due to the patient withdrawing from the study or from
not having a follow-up. The probability of surviving at any time ti is calculated as
the product of the probability of surviving at each of the times before ti, i.e. from








where S(t) is the probability of surviving longer than time t, ti is the time interval,
tn is the maximum survival time in the data, ai is the number of patients known to
have survived at time ti and di is the number of patients who have died at ti.
The Log Rank test is a hypothesis test that compares the survival curves of two
independent groups or clusters [30]. The test can be approximately distributed as
a Chi-Squared statistic. The test is used to identify if two clusters are statistically
di↵erent from one another. Essentially the test compares the observed and the
expected survival rates for two clusters. The null hypothesis for the test states
that two independent groups or clusters have equal survival rates. The degree of
freedom is calculated as the number of outcomes (dead or alive) minus one which







Where n is the total number of clusters being compared, Oi is the observed number
of deaths in each cluster and Ei is the expected number of deaths in each cluster.
The Log Rank test can be done pair-wise for each cluster in the group to identify if
each cluster is statistically significant from the other clusters. When performing a














where, at time t, N1 and N2 are the number of survivors in cluster 1 and 2 respec-
tively, O1,2 is the total number of deaths observed in both clusters and N1,2 is the
total number of survivors in both clusters. The Chi-Squared value can then be used
to determine the p-value. A p-value less than 0.05 corresponds to rejecting the null
hypothesis; meaning there is statistical significance between the survival rates of the
two clusters. The Kaplan-Meier and Log Rank tests were jointly conducted using
the survdi↵ function in the R statistical software [55].
3.2.2 Clustering Results for Multiple k Values
Pair-wise Log Rank tests were conducted for k values ranging from 5 to 9. The
results of each clustering are presented below.
Figure 3.4 presents the Log Rank test output for k values from 5 to 7. For
k = 5, only cluster One is statistically di↵erent from other clusters with a p-value
less than 0.05. The remaining clusters have higher p-values, indicating that the
overall survival of the clusters are not statistically di↵erent. Of the total 9 pair-
wise comparisons, only 4 were less than 0.05. For k = 6, clusters Two and Six are
statistically di↵erent from the rest. Even with 60% of pair-wise comparisons, 9 out
of 15, having a p-value higher than 0.05, only two clusters out of the 6 are distinct
from others. Finally, for k = 7, clusters Three, Six and Seven have majority of pair-
wise p-values less than 0.05 in the pair-wise comparisons. However, the majority
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Figure 3.4: Log Rank pair-wise p-values for k values of 5 (top), 6 (middle) and 7
(bottom). P-values less than 0.05 are underlined in red.
of pair-wise comparisons for clusters Five, Four, One and Two have high p-values
indicating that these clusters are not well di↵erentiated from the rest. The results
suggests that a clustering of the patient correlation data into 5, 6 or 7 clusters is
not adequate to produce distinct clusters with di↵ering prognosis.
Clustering of patient data into 8 clusters produced clusters where 75% of pair-
wise p-values, 21 out of 28, were lower than 0.05. Figure 3.5, shows the results of
the Log Rank pair-wise test for 8 clusters. The test indicates that cluster Four is
statistically di↵erent from all other clusters, clusters Two and Six are statistically
di↵erent from 6 out of the 7 clusters, clusters One and Eight from 5 out of 7
clusters and finally clusters Three, Five and Seven from 4 out of 7 clusters. The
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Figure 3.5: Log Rank pair-wise p-values for patient correlation data clustered into
8 clusters. p-values less than 0.05 are underlined in red.
results indicate that all clusters are statistically di↵erent to at least the majority of
clusters.
Figure 3.6: Log Rank pair-wise p-values for patient correlation data clustered into
9 clusters. p-values less than 0.05 are underlined in red.
Clustering of patient data into 9 clusters produced only 66% of pair-wise re-
sults, 24 out of 36, to have p-values less than 0.05. This indicates that the clusters
are less statistically significant when compared to the partitioning of data into 8
clusters. Cluster Two is statistically significant from 7 out of 8 clusters, clusters
One, Three and Nine from 6 out of 8, clusters Five, Six and Seven from 5 out of 8
and cluster Four from 4 out of 8. It is interesting to note that although the total
sum of squares decreased, the clustering of patients into 9 clusters did not produce
more significant results when compared to 8 clusters.
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Clustering of patient correlation data into 8 clusters captures enough patient
cohorts with variable survival times when compared to the clustering of data into 5,
6, 7 or 9 clusters. As mentioned above, the 8 clusters had the highest percent of pair-
wise p-values less than 0.05. Previous studies using the TCGA data set produced
7 clusters [11]; of which 3 out of 7 were majority IDH mutants with lower grade
gliomas and 4 out of 7 were primarily IDH wild type with majority glioblastomas.
Similarly, in our clustering results, 3 out of the 8 clusters, clusters Two, Four and
Six, were primarily IDH mutant with majority lower grade gliomas. Likewise, 4
out of 8 clusters, clusters Three, Five, Seven and Eight were IDH wild type with
majority glioblastomas. Only cluster One, which is composed of almost an equal
ratio of IDH wild type and mutants, was not identified in literature. Also of note,
cluster Four from the 8 cluster result was split into two clusters, cluster Two and
Seven, for the 9 cluster result. A comparison of the pair-wise p-value in Figure 3.6,
show that clusters Two and Seven are not statistically di↵erent in the 9 cluster result
whereas cluster Four can be di↵erentiated from all clusters in the 8 cluster results.
In conclusion, clustering of data into 8 clusters was chosen as the best clustered
result for the patient correlation data.
Now that a representative cluster is identified, the 8 clusters will be the input of
the data mining investigation conducted in Section 4.3. The data mining procedure
will allow us to identify molecular attributes that map each sample into its respective
cluster. This in turn allows us to map new patient data into the 8 clusters without
performing the k-means clustering procedure again. A discussion of each of the
clusters from the 8 cluster results is found in Section 3.2.3.
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3.2.3 Eight Clusters Result
Cluster IDs for each sample was outputted by the native k-means function in
MATLAB. The cluster IDs along with clinical data and relevant molecular attributes
detailed in previous TCGA studies [11] were ingested into Neo4j. Neo4j is a graph
database platform used for the querying and visualization of the cluster data [32].
For a more detailed discussion on graph databases and Neo4j, refer to Section 3.3.
The following figure, Figure 3.7, provides the block definition diagram of the TCGA
patient Neo4j node with its property names and data types. Once ingested, relevant
properties of a cluster can be queried using Neo4j’s native Cypher query language
[19].
Figure 3.7: SysML Block Definition Diagram of the TCGA patient Node in Neo4j.
Table 3.1 provides the total number of samples, the average age of patient, the
average survival time measured in days, the IDH mutation count and the type of






Avg. Age Avg. Time Glioma Type
1 130 52.7 585.5
LGG: 35
GBM: 95
2 119 40.6 840.0
LGG: 94
GBM: 25
3 134 53.1 557.5
LGG: 46
GBM: 88
4 122 43.7 781.2
LGG: 122
GBM: 0
5 139 55.7 437.8
LGG: 36
GBM: 103
6 125 40.4 717.2
LGG: 116
GBM: 9
7 129 57.3 472.5
LGG: 55
GBM: 74
8 121 56.8 474.2
LGG: 7
GBM: 114







































































Table 3.2: Relevant molecular attributes of each of the 8 clusters.
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Figure 3.8: Kaplan-Meier survival curves for each cluster.
of the disease; LGG is Lower Grade Glioma and GBM is Glioblastoma. Table 3.2
provides some of the relevant molecular attributes identified in literature [11] and in
Figure 1.4 for each of the clusters. All mutation data has two attributes: 1 signifies
a mutated gene and 0 a wild-type gene. The average of the unnormalized EGFR
copy number data is also provided to identify any amplification in the gene. Figure
3.8, provides the Kaplan-Meier survival curves for the eight clusters.
Although the clusters do not partition exactly compared to previous studies
[9, 11], there are identifiable molecular attributes in the clusters which validate the
respective clinical findings. For example, IDH mutations in gliomas are characterized
as having an early age of diagnosis with longer survival rates than IDH wild-type
gliomas [11]. Most brain tumors with IDH mutations are also diagnosed as Lower
Grade Gliomas. These findings are reflected in clusters Two, Four and Six which
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all have majority IDH mutations, and the patients have relatively younger age at
diagnosis and relatively long survival time and probability (slowly sloping survival
curves). The majority of the patients in these clusters are diagnosed as Lower Grade
Gliomas as well. On the contrary, patients harboring IDH wild-type tumors have
older age at diagnosis and poor prognosis with short survival times (steep survival
curves). These tumors are often diagnosed as Glioblastomas. Clusters Three, Five,
Seven and Eight reflect the clinical attributes found in IDH wild type tumors.
A closer look at the clustering also reveals clusters that potentially coincide
with clusters identified by Caccarelli, et al. [11]. Clusters Two and Six are both
characterized with a majority of IDH, TP53 and ATRX mutations. These molecular
attributes are also reflected in the G-CIMP-low and G-CIMP-high clusters in Figure
1.4. All IDH wild type clusters also have relatively high EGFR amplification values,
indicating that these clusters form the Classic-like, Mesenchymal-like, GBM and
PA-like partitions represented in Figure 1.4. With clinical findings validated by
select molecular attributes, the 8 cluster result provides a usable training set for the
data mining investigation described in Chapter 4.
3.3 Querying Results using Graph Databases
3.3.1 Graph Databases
Traditional databases follow the relational paradigm where data is grouped
into tuples and relations. This model organizes data into tables or relations where
each tuple or row is a data object or entity with columns defining the attributes
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of the entity. Graph databases deviate from this traditional model; instead of rows
and columns, graph databases use nodes and edges to represent and store properties
and relations of data. Graph databases provide flexibility in defining data entities
and stress the relation between entities of data.
Graph databases are a subset of the NoSQL database paradigm which aims to
address limitations of relational databases (RDBMS). NoSQL stands for “Not Only
SQL,” which emphasizes performance and scalability than rigidity of data. This
paradigm is a result of rapid growth in web services such as social networks which
have flexible and non-rigid data entities that are highly connected. This allows the
insertion of data entities that may not have the same attributes as others into the
database without losing application functionality. This flexibility means that the
database designer does not have to excessively design and plan the database before
ingesting data.
Graph databases as the name implies, are based on graph theory and are
comprised of a set of nodes, edges and properties.
Nodes Represent entities or data objects in the database such as a person or a social
network account. Nodes are analogous to rows in RDBMS.
Edges Represent relationship between nodes. Edges may be directed or undirected
in graph databases. Edges di↵erentiate graph databases from RDBMS, where
relationships are not explicitly represented.
Properties Represent the attributes of each data entity. These are analogous to
columns in RDBMS. Edges may also contain properties in a graph database.
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The true advantage of graph networks is in the scalability and flexibility of the
data that it can contain. They are exceptional in handling search and queries when
working with large volumes of data and in areas where data topology or connectivity
is important. Examples of graph database employed successfully include Google’s
Knowledge graph [52], Twitter’s FlockDB, and many more. Applications in biology,
chemistry, and the semantic web are examples of fields that can more naturally be
represented by graph databases.
Graph databases are slowly becoming more common in bioninformatics so-
lutions. They are helpful in storing genome, protein and other views of the hu-
man body while enabling creation of the web of connections between these di↵erent
views. When working with human genome data, RDBMS are adept at representing
the genome attributes of single individuals. However, graph databases allow the
storage, search and queries of data as well as the relationship between individual
entities in an e cient and speedy manner.
3.3.2 Neo4j Graph Platform
Neo4J is the leading open-source graph database platform available at the
moment. It is touted to be able to handle billions of records including nodes and
edges while maintaining search and query support. Neo4j has been used as the
primary graph database solution to large-scale data projects. For example, Neo4j
powers Bio4j which is an aggregated knowledge base for protein related information
accrued from disparate sources such as Gene Ontology, NCBI Taxonomy etc [40].
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Data storage in Neo4j is dissimilar to relational database management systems
(RDBMS). Whereas RDBMS use pre-defined tables with often disjointed relation-
ship between entities, Neo4j leverages a graph storage structure. Data modeling is
much more flexible and easier as di↵erent data entities can be added or changed at
any time. RDBMS on the other hand require upfront development of the logical
model and data types sources need to be known ahead of time. Querying in Neo4j
is much faster than in RDBMS where relationship between entities are not explic-
itly defined. The graph structure of Neo4j allows natural querying regardless of
the number of relationships. Neo4j is a highly reliable, available and fault-tolerant
platform that complies with modern RDBMS database standards. Much like ora-
cle databases, Neo4j is fully ACID compliant [32]; this means all transaction with
the database are processed reliably and validly even in the event of failures or user
errors.
ACID Compliance. Acid compliance is defined as having the following attributes:
Atomicity If a transaction fails, the database will be una↵ected.
Consistency Ensures any and all transactions can change data only in predefined
or valid ways.
Isolation Any data being modified during a transaction cannot be accessed until
the transaction is complete.
Durability All complete transactions will be reflected in the database.
Neo4j is now widely accepted as the standard in graph database enterprise solution.
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Figure 3.9: The label property graph model of Neo4j.
As mentioned in Section 3.3, Neo4j employs Nodes to store data attributes
and properties, and edges to store relationships. Nodes are connected by edges and
may have one or more labels-groupings of nodes into sets. Labels and properties
are indexed for optimized querying. Figure 3.9, shows a simple schematic of the
structure of Neo4j. The two nodes represent a person, which is identified by the
node label. The two nodes are connected by two relationships which can be directed
or undirected and finally, the nodes contain attributes specific to each node.
Neo4j can be embedded in Java applications. For the purposes of this thesis,
Neo4j Community Edition 3.4.5 was used with Neo4j dependency added via Apache
Maven. Apache Maven is a build automation tool that dynamically downloads Java
libraries from an online central repository. Java version 8 and 11 are supported by
current versions of the Neo4j java driver. Neo4j also supports the Cypher Query
Language which allows for e cient querying and updating of graphs [19]. Cypher
o↵ers the full range of features expected from a RDBMS Query Language optimized
for graph databases.
From figure 3.9, it is easy to see how Neo4j’s structure can be leveraged to not
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only store and query data but employ graph algorithms to garner more insights into
the data. Neo4j o↵ers a suite of algorithms used to compute metrics of graphs of
nodes and relationships. Neo4j o↵ers centrality algorithms which help in determin-
ing the importance of nodes in a network and path finding algorithms that allow to
evaluate the availability and length of routes. Neo4j also o↵ers community detec-
tion algorithms that evaluate if there are clusters or partitions of nodes. With the
integration of data from multiple domains, Neo4j is an ideal tool to visualize and
query networks of biological data from a database storage and query perspective.
The results of the clustering performed in this thesis can be downloaded as a Neo4j
database upon request.
3.4 Discussion
This chapter provided an overview of the patient data, the clustering analysis
and the results of the clustering analysis. With high-dimensional data, we employed
the Jaccard index to create a correlation matrix capturing how similar a patient is to
another based on four patient views (Mutations, Copy Number, DNA methylation
and mRNA expression). A clustering analysis was conducted using the k-means
algorithm to then partition the patients based on molecular similarity. The idea is
that molecular similarity will lend itself to similar prognosis. The clustering results
were then validated using the Kaplan-Meier and Log Rank tests and corroborated
with literature. The results are then uploaded to the Neo4j graph database for
querying and visualization.
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As sequencing technologies advance, patient data will become more precise
and abundant. However, transforming the raw data for functional use requires new
frameworks and algorithms. We provide a straightforward and e↵ective approach by
using the k-means algorithm to transform independent numerical patient data into
cohorts with similar characteristics. This is in no way a novel approach, however,
this approach combined with classification and semantic modeling, discussed in the
subsequent chapters, create a framework for e↵ectively transforming the patient
data into functional models.
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Chapter 4: Decisions Supported by Data
4.1 Weka: Open-Source Data Mining Application
4.1.1 Weka Explorer
Data mining helps in elucidating the hidden patterns and intelligently ana-
lyzing the vast sources of data that is being generated and stored nowadays. Data
mining is defined as the process of discovering patterns in data in an automatic or
semiautomatic way [56]. In data mining, the data will take the form of a set of
examples – examples of sepal length of flowers. The output of data mining is the
predictions on new examples based on the previous examples or data – the species to
which a flower belongs to based on its sepal length. The Waikato Environment for
Knowledge Analysis (Weka) is an open-source software developed at the University
of Waikato, New Zealand that provides multiple algorithms and tools to analyze
large data sets and provide functional insights into the data [56].
Weka provides implementations of data analysis and predictive modeling soft-
ware that can be used via an interactive graphical user interface or via Java APIs
(Application Programming Interfaces). Weka provides methods for most of the
important data mining problems ranging from regression, classification, clustering,
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Figure 4.1: The Weka Explorer GUI Menu.
association rule mining and attribute selection. It also provides a workbench which
allows for data pre-processing and data visualization. The easiest way to use Weka’s
algorithms and tools is via the Weka Explorer GUI, depicted in Figure 4.1. TheWeka
Explorer has six primary tabs which are summarized below.
• Preprocess Choose and modify dataset for investigation.
• Classify Train learning schemes and evaluate the schemes through classifica-
tion or regression.
• Cluster Learn clusters for the dataset.
• Associate Learn and evaluate association rules for the dataset.
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• Select attributes Select attributes of interest from dataset for learning scheme.
• Visualize View 2-D plots of data and other diagrams like decision trees.
Weka is written in Java and can be run on Linux, Windows and Macintosh operating
systems. Weka version 3.8.3 was used as part of this thesis.
4.1.2 Instances, Attributes and ARFF format
The input to a Machine learning function is a set of instances or examples. The
input data set is expressed as a set of independent instances each with its own set of
predetermined numeric and/or non-numeric attributes. Weka broadly classifies all
attributes as either numeric or nominal [56]. Numeric attributes measures numbers
that are either real or integer valued. Nominal attributes are values that are non-
numeric symbols and serve as labels or names. Boolean attributes are a special case
of nominal attributes-often designated as true or false, however they can also be
characterized by the standard integer convention.
The bulk of the time in a data mining investigation is consumed by input
preparation and processing. Weka uses the attribute-relation file format (ARFF)
for all input of data. The ARFF file is an ASCII text file that lists a set of instances
that share a common list of attributes. Figure 4.2, depicts the contents of an ARFF
file relating to weather data. The file is composed of two sections. The header
section contains the name of the relation and a list of attribute definitions. Each
attribute is defined by its name and its data type. The final attribute definition is
the attribute to be classified. For example, in Figure 4.2, a learning scheme will be
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created to determine if one should play or not based on the weather data instances
provided. The second section is the data section which contains instances of data
with predetermined or observed values for the attributes.
%ARFF file for weather data with some numeric features
@relation weather
@attribute outlook {sunny, overcast, rainy}
@attribute temperature numeric
@attribute humidity numeric
@attribute windy {TRUE, FALSE}

















Figure 4.2: Example of an ARFF file content.
Weka provides the ARFF-Viewer tool to view, edit and create ARFF files.
The patient data was first saved as a comma separated file (csv) containing the
relevant molecular information and the Cluster ID for each patient. It is to be
noted that the first row of the csv files must contain the name of the attributes with
each subsequent row being the instances, otherwise, Weka will not be able convert
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the file into an ARFF file. The csv file was then uploaded into ARFF-Viewer from
which attributes can be selected or deselected as well as the attribute to be classified
can be selected. The csv file can then be saved as an ARFF file by simply going to
File and Save As.
4.2 Decisions made from Data
4.2.1 Decision Trees
Decision trees are decision support tools that enable deduction of a set of con-
clusions from a set of observations. Decision trees are used for visual and explicit
representation in decision analysis. In Machine Learning, each node in a decision tree
represents an attribute and each branch is the outcome of the conditional statement
on the attribute. Decision trees can be viewed as the output of the mathematical
and computational algorithms used to categorize and generalize a dataset. Decision
trees are used ubiquitously throughout the field of medicine, especially in the classi-
fication of diseases based on the structure of a↵ected tissue and molecular attributes.
Although not perfect, decision trees provide an easy to understand representation
and heuristic to complex problems and questions.
Rules in data mining can be characterized as if-then patterns found within
the data. Classification rules enable the mapping of an instance or an example to
a class or a category. The precondition of a rule is the series of branches that is
traversed to reach the consequent, which is the conclusion or the class that apply to
the instances covered by the rule. It is easy to generate a set of classification rules
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Figure 4.3: Creation of rules from a decision tree (Source: Freitas, et al. [20]).
directly o↵ a decision tree. A simple pass through the branches of the decision tree
from the root to the leaf is enough to generate a rule. This procedure is illustrated
in Figure 4.3.
The C4.5 algorithm summarized in Section 4.2.2, produces a decision tree
based on the molecular attributes of each cluster. The consequent of the tree is
the cluster the instance in question belongs to. Each of the node in the tree is
a molecular attribute and each of the branches from the node is the path of a
conditional statement on the node. A traversal from the root to each of the leaves
of the tree will produce unique rules that allow for the classification of instances
into the clusters. The classification rules are extracted form the C4.5 generated tree
using the PART rule generator in Weka [56].
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4.2.2 C4.5 : Divide and Conquer
The C4.5 algorithm is a supervised learning algorithm that allows for the clas-
sification of new instances from a training set. The algorithm uses a univariate
decision tree approach where splitting of the decision tree is based on a single at-
tribute at each node. The algorithm utilizes the concept of ‘entropy,’ which is the
measure of disorder of the data [8]. Weka implements a java version of C4.5 called
J48.
Figure 4.4: Entropy is a measure of how ‘impure’ the data is.
Entropy in data mining is the measure of how much disorder or uncertainty is
in the data. As depicted in Figure 4.4, a low entropy is characteristic of homogeneous
data where most of the instances belong to a particular class. High entropy, on the
other hand, has uncertainty and variance among the classification of the instances.









where j is the total number of classes, |ni| is the number of instances of class i and
|n| is the total number of instances in the training set in a particular node.
Information gain is described as the amount of information that is gained
by knowing the value of an attribute. That is, information gain determines which
attribute(s) in a set of training attributes is most useful for distinguishing between
the classes to be classified. A decision tree is constructed on those attributes which
return the highest information gain. Information gain is a function of the entropy of
all instances of the parent node and the entropy of the instances split on a specific
attribute. Information gain is defined as
Gain(p, x) = E(p)  E(l|x)  E(r|x) (4.2)
where p is the training set before the split i.e. parent node, l and r are the subset of
the training set that is split based on the value of the attribute x i.e. child nodes.
The C4.5 algorithm uses entropy and information gain to divide the training set
into more homogeneous subsets to create decision tress [8]. A step-by-step summary
of the algorithm is given below.
1. Check if all instances belong to the same class, then the tree is simply a leaf
labeled with the class.
2. Otherwise, for each attribute, calculate the information gain.
3. The attribute with the highest information gain will be the best splitting
attribute and the parent node.
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4. Repeat steps 2 and 3 at each parent node recursively.
5. Stop splitting when all instances are classified.
6. Prune to generalize the decision tree.
Decision trees created from a training set often contains unnecessary structure and
bias. Pruning is done to simplify and generalize the decision tree. C4.5 adopts the
strategy of subtree replacement where a subtree is replaced by a leaf node if overall
information gain is only marginally decreased. Although the accuracy of the tree on
the training set is decreased, pruning may increase the accuracy on an independently
chosen test set.
Select molecular information of all the patient instances from the clustering
data were uploaded, along with the cluster label, into Weka. The C4.5 algorithm
was employed to create a decision tree based on the input data. The PART rule
generator was used to traverse the tree and generate rules. The results of the decision
tree analysis is discussed in the following section.
4.3 Decision Tree Results
4.3.1 Decision Tree Input
Clinical trials are experiments conducted to understand the e cacy of a new
drug or treatment on human subjects. The NCI-MATCH program is the primary
cancer clinical trial at the National Cancer Institute [31]. The program chooses
patients based on the genetic makeup of their tumors. Genomic sequencing and
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other tests are used to determine the genetic makeup of the cancer cells in the
patients and patients with identifiable genetic changes that match with treatments
in the trial then receive that treatment. The clinical trial assays a subset of the
genome identified to be cancer driver genes. This subset of genes will be used as the
input to the decision tree.
A whole-genome sequencing of patients in a clinical trial is time consuming
and expensive. As such, certain biomarker assays were created that target specific
genes that play an important role in cancer development. Oncomine assays are
multi-biomarker genomic assays designed for cancer research and used as part of
NCI-MATCH [44]. The assay detects mutations, insertions and deletions and copy
number changes in almost 120 unique cancer driver genes.
Rather than using the whole genome, the oncomine cancer driver genes were
used; significantly reducing the genes per patient from approximately 11,000 to
115 genes. This allows for the targeting of cancer driver genes when creating the
decision tree and is a better representation of the data a physician will have when
choosing treatment options. For each patient view (mRNA, mutation, copy number
and methylation), the cancer driver genes were selected and stored in a csv file.
This essentially pruned the data from having approximately 44,000 attributes to
451 attributes for each patient. A schematic of the selection of genes is presented in
Figure 4.5. Each instance in the training set now contained the select cancer driver
gene data for each patient view and the cluster label used for classification. The csv
file was then saved as an ARFF file using the ARFF-viewer tool in Weka and was
inputted into the C4.5 algorithm.
72
Figure 4.5: Schematic of selecting attributes for decision tree input.
4.3.2 Decision Tree Rules
The PART rule generator extracted rules from the decision tree created by the
C4.5 algorithm. A total of 75 rules were extracted from the training set. Figure 4.6
shows the first three rules outputted from the C4.5 algorithm. The precondition of
the rules is a series of molecular attributes ANDed together and the consequent is
the cluster to which a sample would belong to based on the rules. The number to the
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left in the parenthesis is the number of instances classified correctly and the number
to the right is the number of instances incorrectly classified based on the rule. For
example in Rule 1 in Figure 4.6, if all the molecular attributes and respective values
are satisfied in a sample, then the sample would be classified into cluster 4. A total
of 110 instances were classified using this rule. The remainder of the rules can be
found in the Appendix.
=== Classifier model (full training set) ===
PART decision list
------------------
STAT3_scnaq > 1 AND
MAGOH_scnaq <= 0 AND
PPP2R1A_scnaq <= 1 AND
DDR2_scnaq > 0 AND
ATRX_scnaq <= 1 AND
FOXL2_scnaq <= 1 AND
NFE2L2_scnaq <= 1: Four (110.0)
DDR2_scnaq > 1 AND
JAK1_scnaq > 0 AND
ERBB2_scnaq <= 0 AND
NRAS_scnaq <= 1 AND
GNA11_scnaq <= 0: Six (6.0/1.0)
DDR2_scnaq > 1 AND
JAK1_scnaq > 0 AND
ERBB2_scnaq <= 0 AND
MAP2K2_scnaq <= 1 AND
JAK1_scnaq > 1 AND
EZH2_mRNA > 0 AND
NTRK3_mRNA <= 1: Three (27.0)
Figure 4.6: The first three rules out of seventy five outputted by the C4.5 algorithm.
As with any model, the decision tree model does not encapsulate the training
set perfectly. The model had an accuracy of 59.32%. The decision tree was able
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to classify 595 out of 1003 instances into the correct clusters using the rules. 408
out of 1003 instances were classified into the wrong cluster based on the rules.
Multiple attempts of running the algorithm on the data set produced the same
result suggesting that this is the best output of the algorithm.
Given these results, the decision tree however was able to give new insights
into the molecular data. Out of the four patient views (mRNA, mutation, copy
number and methylation), the rules were primarily composed of copy number and
mRNA attributes. This potentially suggests that mRNA and copy number data
provide more information to partition the instances into clusters than mutation
and methylation data. However, more than likely, this could be a consequence of
mutation and methylation patient views lacking data as discussed in Section 3.1.1.
Of the 451 di↵erent attributes, only 143 attributes were deemed relevant to the
partition of the clusters. An analysis of these attributes and their function can
provide more insights into pathways of cancer development in brain cancers. Also
of note, out of the mutation data only the IDH mutation was represented in the
rules, suggesting that indeed IDH mutation plays an important role in brain cancer
development.
A confusion matrix is also outputted as part of the results. A confusion matrix
is a table that is created to describe the performance of a classification model. The
confusion matrix in Figure 4.7 suggests that cluster Four, which had the highest
number of p-values less than 0.05, was the best classified cluster with 90% of the
instances classified correctly. Clusters Five, Six and Seven had the next best classi-
fication results with nearly 60% of the instances classified correctly. The remaining
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=== Confusion Matrix ===
a b c d e f g h <-- classified as
71 5 10 12 10 6 5 11 | a = One
6 53 6 0 17 18 9 10 | b = Two
14 11 68 0 4 17 4 16 | c = Three
10 1 0 110 0 0 0 1 | d = Four
8 12 3 0 81 2 19 14 | e = Five
9 19 6 0 3 81 3 4 | f = Six
4 7 10 2 13 7 83 3 | g = Seven
13 6 11 3 16 3 5 48 | h = Eight
Figure 4.7: Confusion matrix from C4.5 output which depicts where each instance
from each cluster was classified into based on the rules.
clusters fared worse with less than 55% accurate classification. Clusters Two and
Eight had the worst accuracy with only 44% and 40% correct classification respec-
tively. Considering clusters Two and Eight were statistically distinct from 6 out of
7 of the other clusters, the classification results are surprising. This implies that the
attributes that contribute to the di↵erent prognosis of these clusters are not being
captured properly in the decision tree model or that the subset of the genome used
in the assay is not su cient to capture the partitions.
Even with accuracy lacking for clusters Two and Eight, the decision tree model
provides a good framework to classify the majority of samples into a majority of
the clusters. Unlike other high accuracy Machine Learning (ML) models which use
neural nets and other learning schemes, decision tree models output the actual func-
tion for classification via the rules. Most ML algorithms are black box algorithms
with hard to understand internal behavior; they provide the classification result but
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not the mapping function. The availability of the rules from a decision tree model
allows clinicians to validate and test the rules and allows for a straightforward im-
plementation of a semantic model, which is discussed in the next chapter.
4.4 Discussion
This chapter provided the classification method used to extract a decision tree
from the clustering results. Classification determined select molecular attributes
of each cluster allowing for any new data to be classified immediately rather than
using the k-mean clustering again. The C4.5 algorithm, implemented as J48 in
Weka, employed the concept of data entropy to partition the instances of patient
gene data. The classification, although not perfect, provides a set of mapping rules
to classify the majority of instances into the clusters.
The clustering and the classification framework provides a viable method to
handle high-dimensional patient data and to extract usable attributes based on
patient similarity. As more data is made available, this application and the results
of the method will become more robust to be used for clinical purposes. A semantic
model can now be created containing the infrastructure to model the Glioma domain
and data. A semantic model, as discussed in the following chapter, allows for the
representation of the Glioma domain along with the clustering and classification
results in a dynamic model.
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Chapter 5: Ontologies Supported by Data
5.1 Semantic Model Software Architecture
The software organization for the development and generation of the semantic
model is given in Figure 5.1. The semantic model consists of glioma-specific ontolo-
gies, instances of data and rules derived from the classification results. The soft-
ware model is implemented in Java with the ontology created using the RDF/OWL
framework and the data imported from text files.
Figure 5.1: Software Architecture of generation of semantic models.
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Generation of the semantic model begins with the creation of domain-specific
ontologies in OWL. In this case, a glioma, TCGA patient and CCLE cell line ontol-
goies are created to capture the domain space. Each ontology is given ontological
descriptions, hierarchy of classes and data and object properties. Classification rules
from the data mining investigation and domain-specific constraints are then trans-
formed into Jena rules to be read by the model. Finally, data is ingested into the
model from TCGA and CCLE text files. The Data model reads and imports the
data. A visitor design pattern is implemented to transfer the data model to the Jena
Semantic model. Once all the components of the model are created, the semantic
rules can be applied to the model and applications can visit, query and reason with
the model.
5.2 Glioma Ontology Models
Protege is an open source suite of tools that facilitate the building of knowledge
bases through ontologies [37]. It is used to create domain ontologies, specify domain
relationships, datatype properties, object properties and specify constraints on said
domains and properties. Protege was used in the creation of the glioma-specific
ontology. A brief and simplified description of each of the ontologies is provided
below.
Figure 5.2 provides a simplified representation of the Glioma ontology. The
Glioma class is further broken down into the IDH wild-type and IDH mutation sub-
classes consistent with literature [11] and classification results. The IDH wild-type
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and mutation classes are then stratified further based on the classification results
from Section 3.2. This ontology captures the domain relationship via sub-class
properties and allows reasoning of instances assigned from the leaf classes up to the
root Glioma class.
Figure 5.2: Glioma Ontology with clusters from classification results.
Figure 5.3 presents the simplified representation of the TCGA patient ontology.
The ontology incorporates patient clinical data and the molecular attributes deemed
important by the data mining investigation. Note that only a select few molecular
attributes are shown in the figure. This ontology enables the ingestion of patient
instances from the TCGA patient data into the semantic model and allows mapping
of patients to the glioma clusters based on the datatype properties of each instance.
The mapping is defined via the hasCluster object property.
Figure 5.4 presents the simplified representation of the CCLE cell line ontology.
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Figure 5.3: TCGA patient ontology.
The ontology incorporates all 143 molecular attributes considered relevant by the
data mining investigation. Note that only a select few molecular attributes are
shown in the figure. The cell line ontology enables the creation of cell line instances
which are ingested from the CCLE data model. Once all cell line instances are
created, the rules will map each cell line to a Glioma cluster via the hasCluster
object property.
The ontologies provide a simplified but adequate representation of the Glioma
domain and allow data to be created as instances of the ontology. New patient
data can now be ingested into the model and with the help of the rules can be
mapped immediately to the relevant clusters. Likewise, as more cell line data is
produced, it can also be incorporated into the model seamlessly. Although the
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Figure 5.4: CCLE cancer cell line ontology.
current ontologies are created for the purposes of matching cell lines to clusters,
more semantic description, domains and data can be added to the model in the
future. As the model is refined and given more functionality, it can be used for
more complex tasks and narrower reasoning.
5.3 Mapping of Preclinical Models
We proposed that a semantic approach will enable the rational selection of pre-
clinical models and patients for clinical trials. The Glioma semantic model provides
a framework to achieve these goals. The Glioma ontologies along with the rules
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allow for the ingestion of patient and cell line model data and allow for the map-
ping and selection of models based on molecular similarity. This section provides a




//Propagation Rule 01: Propogate Class hierarchy...
[rdfs01: (?x rdfs:subClassOf ?y), notEqual(?x, ?y) ->
[(?a rdf:type ?y) <- (?a rdf:type ?x)] ]
//Rule 01:
[ Rule01: (?x rdf:type af:Ccle) (?x af:hasSTAT3_scnaq ?stat)
(?x af:hasMAGOH_scnaq ?ma) (?x af:hasPPP2R1A_scnaq ?pp)
(?x af:hasDDR2_scnaq ?dd) (?x af:hasATRX_scnaq ?atr)
(?x af:hasFOXL2_scnaq ?fox) (?x af:hasNFE2L2_scnaq ?nef)
greaterThan(?stat, 1.0) lessThan(?ma, 1.0)
greaterThan(?ma, -1.0) lessThan(?pp, 2.0)
greaterThan(?pp, -1.0) greaterThan(?dd, 0.0)
lessThan(?atr, 2.0) greaterThan(?atr, -1.0)
lessThan(?fox, 2.0) greaterThan(?fox, -1.0) lessThan(?nef, 2.0)
greaterThan(?nef, -1.0) -> (?x af:hasCluster af:ClusterFour) ]
//Rule 03:
[ Rule03: (?x rdf:type af:Ccle) (?x af:hasDDR2_scnaq ?dd)
(?x af:hasJAK1_scnaq ?jak) (?x af:hasERBB2_scnaq ?erb)
(?x af:hasMAP2K2_scnaq ?map) (?x af:hasEZH2_mRNA ?ez)
(?x af:hasNTRK3_mRNA ?nt) greaterThan(?dd, 1.0)
greaterThan(?jak, 0.0) equal(?erb, 0.0) le(?map, 1.0)
greaterThan(?map, -1.0) greaterThan(?ez, 0.0) le(?nt, 1.0)
greaterThan(?nt, -1.0) -> (?x af:hasCluster af:ClusterThree)]
Figure 5.5: Classification Rules transformed to Jena Rules.
Classification rules from the data mining investigation was first transformed
into the standard format of Jena Rules. Figure 5.5 depicts the class propagation
and classification rules in the Jena format. The propagation rule propagates class
hierarchy; placing constraints on the type an instance can be. The remaining rules
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are classifier rules. For example, in Rule 01, the reasoner traverses the RDF knowl-
edge graph of CCLE instances and checks if the rule constraints are satisfied for
each instance. If the rules are satisfied then the CCLE instance is mapped to the
ClusterFour class in the Glioma Ontology via the hasCluster object property. The
rules can be executed at any time creating a dynamic and responsive model.
Figure 5.6 depicts the graph transformation that occurs when a rule is sat-
isfied. In the figure, an instance of the CCLE class with its particular molecular
attribute satisfies the rule which creates an object property from the instance to
the ClusterTwo class instance. From a semantic point of view, the CCLE instance
now has access to all class descriptions and properties of ClusterTwo and its parent
classes. Once all the rules from the classification results are transformed into Jena
rules, they can be executed sequentially and all instances in the Glioma ontology
satisfying the rules will be mapped to the relevant cluster.
Tables 5.1 and 5.2, provides the results of the mapping of preclinical models
to each cluster. The table provides the IDs of CCLE models which responded to
each cluster based on the classification rules. Once all the rules were executed, those
CCLE instances that satisfied the rules were then assigned an object property to
the relevant cluster. An iterator was then used to iterate through the CCLE models
for each cluster. These set of models for each cluster have the closest molecular
similarity to the patients in each of the clusters. The hope is that these subset of
models will lead to better understanding of the e cacy of treatments for a patient
diagnosed into the respective cluster. These models could potentially provide better
prognostic insights into how well the patient might fare to experimental treatment.
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Figure 5.6: Mapping of CCLE instance to Cluster.
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Considering each cluster has di↵erent overall survivability, preclinical trials can also
be tailored to each cluster of patients narrowing the cohort for the trial. With the
selection of preclinical models based on the molecular basis of patients with di↵erent






ACH-000927, ACH-000350, ACH-000345, ACH-000865
ACH-000596, ACH-000769, ACH-000444, ACH-000934
ACH-000523, ACH-000675, ACH-000379, ACH-000816
ACH-000203, ACH-000490, ACH-000461, ACH-000147
ACH-001302, ACH-001740
2 13
ACH-000844, ACH-000731, ACH-000690, ACH-000190
ACH-000523, ACH-000675, ACH-000870, ACH-000399
ACH-000871, ACH-000816, ACH-000358, ACH-000443
ACH-000232
3 34
ACH-000948, ACH-000956, ACH-000052, ACH-000880
ACH-000191, ACH-000245, ACH-000402, ACH-000867
ACH-000805, ACH-000256, ACH-000278, ACH-000352
ACH-000196, ACH-000668, ACH-000178, ACH-000724
ACH-000671, ACH-000595, ACH-000583, ACH-000849
ACH-000391, ACH-000666, ACH-000841, ACH-000610
ACH-000789, ACH-000116, ACH-000751, ACH-000617
ACH-000409, ACH-000090, ACH-000790, ACH-000087
ACH-000955, ACH-000430
4 13
ACH-000788, ACH-000248, ACH-000120, ACH-000253
ACH-000756, ACH-000631, ACH-000769, ACH-000733
ACH-000436, ACH-000363, ACH-000312, ACH-000661
ACH-001111








ACH-000649, ACH-000593, ACH-000516, ACH-000392
ACH-000644, ACH-000978, ACH-000633, ACH-000575
ACH-000971, ACH-000994, ACH-000721, ACH-000178
ACH-000801, ACH-000632, ACH-000250, ACH-000313
ACH-000319, ACH-000980, ACH-000434, ACH-000121
ACH-000614, ACH-000811, ACH-000686, ACH-001302
6 11
ACH-000880, ACH-000867, ACH-000111, ACH-000196
ACH-000595, ACH-000573, ACH-000666, ACH-000177
ACH-000751, ACH-000617, ACH-000090
7 16
ACH-000940, ACH-000402, ACH-000805, ACH-000903
ACH-000239, ACH-000357, ACH-000176, ACH-000200
ACH-000062, ACH-000398, ACH-000149, ACH-000908
ACH-000898, ACH-000567, ACH-000656, ACH-000958
8 31
ACH-000046, ACH-000927, ACH-000457, ACH-000253
ACH-000868, ACH-000739, ACH-000799, ACH-000472
ACH-000476, ACH-000858, ACH-000604, ACH-000685
ACH-000301, ACH-000390, ACH-000019, ACH-000058
ACH-000453, ACH-000737, ACH-000675, ACH-000646
ACH-000442, ACH-000181, ACH-000465, ACH-000341
ACH-000016, ACH-000623, ACH-000344, ACH-000686
ACH-000147, ACH-000568, ACH-001053
Table 5.2: CCLE models which responded to classification rules for clusters 5
through 8.
5.4 Discussion
This chapter introduced the Semantic Web framework and the application
of the framework to the Glioma Domain. The clustering and classification results
are now represented in a simplified Glioma semantic model. The semantic model
consists of the Glioma ontology, the patient ontology, the cell line ontology and
instances of data. We present the Glioma semantic model as a dynamic model
into which new data can be ingested and reasoned for the purposes of mapping to
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prognostically relevant clusters.
The power of the Semantic Web lies in its ability to integrate di↵erent domains
and allow reasoners to reason over these domains. This semantic model serves to
be a small foundation to build a larger, more comprehensive model of the Glioma
domain. Ontologies from disparate domains such as patient symptoms and patient
microbiome can now be created and integrated into the semantic model and rules
can be executed which take into account these disparate domains. The development
of the semantic model can ultimately become a powerful tool in the practice of
precision medicine.
88
Chapter 6: Conclusions and Future Work
6.1 Conclusion
As advances in medical technologies continue to rapidly grow, it is impera-
tive to create frameworks and algorithms that utilize these new streams of data to
ultimately help the patient. In this paper, we provide a semantic model coupled
with a machine learning framework to turn high dimensional patient data into a
dynamic model. We provide an application of this model to bridge the gap between
the disease and preclinical space. This Glioma specific model provides a foundation
onto which other domains can be incorporated to create an all-encompassing patient
model to aid in the practice of precision medicine. The human body is a true system
of systems, and frameworks proposed in this thesis as well as others will be vital to
the understanding of this complex system.
6.2 Future Work
The work done in this thesis makes progress towards a digital twin of a patient.
The digital twin architecture for personalized medicine, presented in Figure 1.8 and
Figure 1.10, lay the foundation to incorporate domains relevant to the treatment of a
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patient. These high-level schematics provide a framework to use semantic modeling
to serve as an ‘operating system’ for patients and opens new digital ecosystems for
improved services and treatment.
Symptoms management apps such as GlioNCI [45], provide an interface for
patients to report their symptoms and their quality of life. And with the advent of
smart wearable technologies, basic clinical instruments such as the electrocardiogram
and other sensing instruments are within the reach of nearly every patient. The
digital twin architecture enables the integration of these apps and other patient
sensing systems to create a comprehensive and real-time model of a patient. We
envision a comprehensive model, validated by medical practitioners, incorporating
patient data, real-time patient dynamics, ontologies, models and rules governing
treatment and diagnosis to aid future clinicians in practicing precision medicine.
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Appendix A: Classification Rules
The following is the full set of rules outputted by the C4.5 Decision Tree
algorithm.




STAT3_scnaq > 1 AND
MAGOH_scnaq <= 0 AND
PPP2R1A_scnaq <= 1 AND
DDR2_scnaq > 0 AND
ATRX_scnaq <= 1 AND
FOXL2_scnaq <= 1 AND
NFE2L2_scnaq <= 1: Four (110.0)
2
DDR2_scnaq > 1 AND
JAK1_scnaq > 0 AND
ERBB2_scnaq <= 0 AND
NRAS_scnaq <= 1 AND
GNA11_scnaq <= 0: Six (6.0/1.0)
3
DDR2_scnaq > 1 AND
JAK1_scnaq > 0 AND
ERBB2_scnaq <= 0 AND
MAP2K2_scnaq <= 1 AND
JAK1_scnaq > 1 AND
EZH2_mRNA > 0 AND
NTRK3_mRNA <= 1: Three (27.0)
4
STAT3_scnaq <= 0 AND
IDH_mut > 0 AND
MAGOH_scnaq > 0 AND
TP53_scnaq <= 0 AND
MAP2K2_scnaq <= 0 AND
SIRT2_scnaq > 0 AND
KLF4_scnaq <= 1: Six (57.41)
5
H3F3A_scnaq > 1 AND
NRAS_scnaq > 1 AND
HRAS_scnaq <= 0 AND
DDR2_scnaq > 1 AND
MAP2K4_mRNA <= 1 AND
AKT3_scnaq > 1 AND
NTRK3_mRNA <= 1 AND
MAP2K2_mRNA > 0: Three (28.0)
6
PPM1D_scnaq > 1 AND
MAGOH_mRNA <= 0 AND
ATRX_mRNA <= 1 AND
KLF4_mRNA <= 1 AND
MAP2K2_mRNA <= 1: Eight (26.0/2.0)
7
PPM1D_scnaq > 1 AND
MAGOH_scnaq <= 0 AND
ERBB2_scnaq > 0 AND
SPOP_mRNA > 0 AND
GATA2_scnaq > 0 AND
RAF1_mRNA > 0 AND
HRAS_mRNA > 0 AND
MYCN_mRNA > 0: One (17.0)
91
8
H3F3A_scnaq > 1 AND
MAGOH_scnaq <= 0 AND
SMO_mRNA > 1 AND
GATA2_mRNA > 1: Three (3.0)
9
STAT3_scnaq <= 0 AND
CCND1_scnaq <= 1 AND
SMARCB1_scnaq <= 1 AND
H3F3A_scnaq <= 1 AND
IDH_mut <= 0 AND
RAF1_scnaq <= 1 AND
EZH2_scnaq > 1 AND
KDR_scnaq > 0: Seven (45.64)
10
H3F3A_scnaq > 1 AND
MAGOH_scnaq <= 0 AND
SPOP_mRNA <= 0: Eight (8.0/1.0)
11
DDR2_scnaq > 1 AND
JAK1_scnaq <= 0 AND
CSF1R_mRNA <= 1 AND
NRAS_mRNA <= 1 AND
RAF1_mRNA > 0 AND
CCND3_mRNA > 0 AND
RAF1_mRNA > 1: One (10.0)
12
H3F3A_scnaq > 1 AND
MAGOH_scnaq <= 0 AND
SIRT2_scnaq <= 1 AND
ERCC2_mRNA <= 1 AND
CIC_mRNA > 0: One (7.0/1.0)
13
PPM1D_scnaq > 1 AND
MAGOH_scnaq <= 0 AND
RHOA_scnaq <= 1 AND
AR_mRNA <= 0: Four (9.0/1.0)
14
DDR2_scnaq > 1 AND
JAK1_scnaq <= 0 AND
STAT3_scnaq > 0 AND
ROS1_scnaq <= 1: Four (4.0/1.0)
15
DDR2_scnaq > 1 AND
JAK1_scnaq <= 0 AND
CCND3_mRNA > 1: Five (3.0)
16
DDR2_scnaq > 1 AND
GNAS_mRNA > 0 AND
ERBB2_scnaq <= 0 AND
GNAQ_scnaq <= 1 AND
EZH2_mRNA <= 1: Seven (12.0/1.0)
17
DDR2_scnaq > 1 AND
RAF1_mRNA <= 0 AND
SETD2_mRNA <= 1 AND
FLT3_scnaq <= 1 AND
GNAS_mRNA <= 0 AND
SMAD4_mRNA <= 1 AND
CTNNB1_mRNA <= 1: Eight (15.0/1.0)
18
DDR2_scnaq > 1 AND
PPP2R1A_scnaq > 1 AND
SMO_mRNA > 1 AND
MAX_scnaq <= 1: Three (9.0/1.0)
19
DDR2_scnaq > 1 AND
PPP2R1A_scnaq > 1 AND
SMO_mRNA <= 1 AND
HRAS_scnaq <= 1 AND
MAGOH_mRNA > 0: Three (14.0/1.0)
20
DDR2_scnaq > 1 AND
PPP2R1A_scnaq > 1 AND
GNAQ_mRNA > 0: Two (5.0)
21
DDR2_scnaq > 1 AND
PPP2R1A_scnaq > 1 AND
AKT3_mRNA <= 0: Seven (3.0)
22
DDR2_scnaq > 1 AND
NTRK1_scnaq <= 1 AND
CCND2_mRNA <= 1: Six (3.0/1.0)
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23
DDR2_scnaq > 1 AND
ERBB2_scnaq <= 0 AND
BTK_mRNA <= 1 AND
SIRT2_mRNA <= 1: Three (11.0)
24
DDR2_scnaq > 1 AND
ERBB2_scnaq > 0 AND
NRAS_mRNA <= 0 AND
AKT2_mRNA <= 0: Three (2.0)
25
DDR2_scnaq > 1 AND
ERBB2_scnaq > 0 AND
NRAS_mRNA > 0 AND
SETD2_mRNA <= 0 AND
GATA2_scnaq > 0: Three (8.0)
26
DDR2_scnaq > 1 AND
RAF1_mRNA > 0 AND
SETD2_mRNA > 0 AND
IDH2_mRNA > 0 AND
NRAS_scnaq > 1 AND
MAPK1_mRNA > 0 AND
KDR_scnaq <= 1: One (21.0)
27
PPM1D_scnaq > 1 AND
CHEK1_scnaq > 0 AND
SMARCA4_mRNA > 0 AND
PIK3CA_mRNA > 0 AND
AXL_scnaq > 1 AND
GNA11_mRNA > 1: Two (5.0)
28
PPM1D_scnaq > 1 AND
GNAS_scnaq <= 0 AND
DDR2_scnaq <= 1 AND
NF1_mRNA > 0 AND
AXL_scnaq <= 1 AND
CBL_mRNA <= 1: One (12.0)
29
PPM1D_scnaq > 1 AND
GNAS_scnaq <= 0 AND
NTRK2_mRNA > 0 AND
NTRK3_mRNA <= 1: Six (10.0)
30
PPM1D_scnaq > 1 AND
RAF1_mRNA <= 0 AND
CBL_scnaq > 0 AND
HIST1H3C_mRNA > 0: Eight (10.0/1.0)
31
PPM1D_scnaq > 1 AND
RAF1_mRNA <= 0 AND
AKT1_meth <= 1: Seven (2.0)
32
PPM1D_scnaq > 1 AND
CSF1R_scnaq > 1 AND
CDK6_mRNA > 0 AND
U2AF1_mRNA > 0: Three (8.0)
33
PPM1D_scnaq > 1 AND
NTRK1_mRNA <= 1 AND
MET_mRNA <= 1 AND
NRAS_mRNA > 0 AND
CCND2_mRNA > 0 AND
MED12_mRNA > 0: One (25.0/1.0)
34
MAP2K4_scnaq > 0 AND
MYC_scnaq > 1 AND
NRAS_scnaq > 0 AND
AKT3_scnaq <= 1 AND
JAK1_mRNA > 0 AND
CHEK2_scnaq > 0 AND
MAX_scnaq > 0: Two (35.0)
35
PPP2R1A_scnaq > 1 AND
IDH_mut > 0 AND
CIC_scnaq > 1 AND
NRAS_scnaq > 0 AND
SOX2_mRNA > 0 AND
BTK_mRNA > 0 AND
JAK1_mRNA > 0 AND
ATRX_scnaq > 0 AND
TP53_meth <= 1: Two (20.83/1.22)
36
MAP2K4_scnaq > 0 AND
FOXL2_scnaq <= 1 AND
DDR2_scnaq <= 1 AND
CCND1_scnaq <= 1 AND
JAK1_scnaq <= 1 AND
KRAS_scnaq <= 1 AND
CCND2_scnaq <= 1 AND
FGFR1_scnaq <= 1 AND
CCND3_scnaq > 0: Five (62.0/2.0)
37
PPP2R1A_scnaq > 1 AND
CCND1_scnaq <= 1 AND
AKT2_scnaq > 1 AND
KDR_scnaq > 0 AND
AKT1_scnaq > 1 AND
NF1_scnaq <= 0: Seven (6.0)
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38
GNA11_scnaq > 1 AND
SMARCA4_scnaq <= 1 AND
AKT2_mRNA <= 0: Two (2.0/1.0)
39
GNA11_scnaq > 1 AND
SMARCA4_scnaq > 1 AND
MAP2K4_scnaq <= 0 AND
NRAS_scnaq <= 1 AND
EGFR_scnaq > 0 AND
KIT_scnaq > 1: Seven (16.78/0.78)
40
IDH_mut > 0 AND
NRAS_scnaq <= 0 AND
AKT2_scnaq <= 0 AND
ERBB2_mRNA <= 1: One (13.63/0.41)
41
SMARCB1_scnaq > 1 AND
NFE2L2_mRNA > 1 AND
ARAF_scnaq > 0 AND
EGFR_scnaq <= 1 AND
FGFR1_mRNA > 0: Five (13.59)
42
HRAS_scnaq <= 0 AND
NRAS_scnaq > 0 AND
SIRT2_scnaq > 0 AND
JAK3_mRNA > 0 AND
NFE2L2_scnaq > 1 AND
FGFR1_mRNA > 0: Six (13.0/1.0)
43
SMARCB1_scnaq > 1 AND
NFE2L2_mRNA > 1 AND
GNAS_mRNA <= 0: Two (5.7/1.0)
44
SMARCB1_scnaq > 1 AND
ROS1_mRNA > 0 AND
CCND2_mRNA <= 1 AND
PIK3CB_mRNA <= 1 AND
FGFR4_mRNA > 0: Eight (18.0)
45
HRAS_scnaq > 0 AND
NF1_scnaq > 1 AND
CDK4_mRNA > 0 AND
TERT_mRNA > 0 AND
CIC_mRNA > 0: Eight (7.0)
46
GNA11_scnaq > 1 AND
ATRX_scnaq > 0 AND
H3F3A_scnaq <= 1 AND
ROS1_scnaq > 0 AND
MAP2K1_scnaq > 0 AND
EGFR_scnaq <= 1 AND
XPO1_scnaq <= 1 AND
HNF1A_scnaq > 0: Five (19.0)
47
MYD88_scnaq > 1 AND
CHEK2_scnaq > 1 AND
MAPK1_mRNA <= 1: One (4.0/1.0)
48
MYD88_scnaq > 1 AND
CTNNB1_scnaq > 1 AND
CCND1_scnaq > 1 AND
SMAD4_mRNA > 0 AND
GNA11_scnaq <= 1 AND
IGF1R_mRNA > 0: Six (16.59/1.59)
49
HRAS_scnaq <= 0 AND
NRAS_scnaq > 0 AND
MDM2_mRNA <= 1 AND
PDGFRA_scnaq <= 1 AND
BTK_mRNA > 0 AND
CCND3_scnaq <= 1: Two (15.59/0.59)
50
HRAS_scnaq <= 0 AND
NRAS_scnaq > 0 AND
CHEK2_mRNA > 0 AND
CDK4_scnaq <= 0 AND
NTRK1_mRNA > 0: Six (7.0/1.0)
51
HRAS_scnaq <= 0 AND
GNA11_scnaq > 1 AND
CCND2_mRNA > 1: Seven (4.0)
52
HRAS_scnaq <= 0 AND
IGF1R_mRNA <= 1 AND
RB1_scnaq <= 1 AND
FOXL2_mRNA > 0: Three (19.0/2.0)
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53
PPP2R1A_scnaq > 1 AND
HRAS_scnaq > 0 AND
MYCN_mRNA <= 1 AND
MYC_scnaq <= 1 AND
RET_scnaq <= 1 AND
CCND1_scnaq <= 1 AND
SMO_mRNA > 0 AND
ERCC2_mRNA > 0 AND
NF1_mRNA <= 1: Seven (21.0)
54
STAT3_scnaq > 0 AND
DDR2_scnaq > 1 AND
MET_mRNA > 0: One (6.0/1.0)
55
STAT3_scnaq > 0 AND
DDR2_scnaq > 1 AND
AKT3_mRNA <= 1: Two (2.0)
56
STAT3_scnaq > 0 AND
DDR2_scnaq <= 1 AND
TP53_mRNA > 1 AND
KLF4_scnaq <= 1 AND
MYD88_mRNA > 1: Five (10.0/1.0)
57
STAT3_scnaq > 0 AND
DDR2_scnaq <= 1 AND
TP53_mRNA > 1 AND
SIRT2_mRNA > 0 AND
EGFR_scnaq <= 1 AND
EGFR_mRNA <= 1: One (8.0)
58
STAT3_scnaq > 0 AND
DDR2_scnaq <= 1 AND
SOX2_mRNA > 1 AND
ERBB4_mRNA > 0 AND
PIK3R1_scnaq <= 1: Two (12.7)
59
STAT3_scnaq > 0 AND
DDR2_scnaq <= 1 AND
SPOP_scnaq <= 0: Two (3.0/1.0)
60
SMARCA4_scnaq > 1 AND
PPM1D_scnaq <= 0 AND
MAPK1_mRNA > 0: Seven (8.18)
61
MYD88_scnaq > 1 AND
PTEN_scnaq > 0 AND
BRAF_scnaq > 0 AND
JAK2_mRNA > 0: Six (7.0)
62
MYD88_scnaq > 1 AND
ERBB2_scnaq <= 0: Seven (7.77/1.59)
63
PPP2R1A_scnaq > 1 AND
IDH_mut <= 0 AND
PDGFRA_mRNA <= 1 AND
ALK_scnaq > 0: Five (14.0)
64
PPP2R1A_scnaq > 1 AND
ATRX_mRNA > 1: Two (4.0)
65
PPP2R1A_scnaq <= 1 AND
NRAS_scnaq > 1 AND
KLF4_mRNA <= 0 AND
BRAF_mRNA > 1: Three (3.0)
66
PPP2R1A_scnaq <= 1 AND
SMARCA4_mRNA > 1 AND
ERBB2_mRNA > 0: Six (6.0/1.0)
67
PPP2R1A_scnaq > 1: Seven (3.0)
68
SMARCA4_mRNA > 1 AND
AXL_mRNA <= 0: One (2.59)
69
SETD2_scnaq <= 1 AND
RHEB_mRNA <= 1 AND
TP53_mRNA <= 1 AND
PPM1D_mRNA <= 1 AND
BRAF_mRNA <= 1: Eight (12.0)
70
RAC1_mRNA <= 0 AND
MAP2K1_mRNA > 1 AND
KLF4_scnaq <= 1: Five (6.0)
71
RAC1_mRNA > 0 AND
PPP2R1A_mRNA <= 1 AND
AKT1_scnaq <= 1 AND
CCND1_scnaq > 0 AND
GNA11_mRNA <= 1 AND
CDK4_mRNA <= 1: Five (9.0)
72
RAC1_mRNA > 0 AND
PPP2R1A_mRNA <= 1 AND
FLT3_mRNA <= 1: Two (9.0)
73
U2AF1_scnaq > 0 AND
RHEB_mRNA <= 1: Eight (8.0/1.0)
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Appendix B: Jaccard Algorithm
function [jaccardNum,jaccardDenom] = jaccard(dataset)
%jaccard: This funciton calcualtes the jaccard values b/w datasets
%For each columnn of data, simply take intersection/union
data = size(dataset, 2) - 1;
jaccardNum = ones(data, data)*-1;
jaccardDenom = ones(data, data)*-1;






for k = 1:1:size(dataset, 1)
%see if data is available
if (~isnan(dataset(k, i)) & ~isnan(dataset(k, j)))
denom = denom + 1;
%check if data is equal
if dataset(k, i) == dataset(k, j)




jaccardNum(i-1, j-1) = numerator;
jaccardDenom(i-1, j-1) = denom;
jaccardNum(j-1, i-1) = numerator;




Figure B.1: Jaccard Algorithm implemented in matlab.
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Appendix C: Neo4j Cypher Queries






Counting nodes with a certain numerical attribute:
MATCH(n:tcga)








WHERE n.property1 = value1 AND n.property2 = value2
RETURN COUNT(n)
Identifying relationships between tcga nodes:
MATCH (n:tcga)-[r:relationshipName]-(k:tcga)
WHERE n.property = value
RETURN COUNT(n)
Creating relationships between tcga nodes:
MATCH (n:tcga)-[r:relationshipName]-(k:tcga)
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